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ABSTRACT 
 
Resistance to antibiotics is on the rise at an alarming pace. The problem is 
exacerbated by the lack of new class of therapeutic agents and targets. Modes of 
resistance include alteration of drug target, modification of ligand, and reduction of the 
intracellular concentration of drug. Dihydrofolate reductase (DHFR) is a validated drug 
target for the treatment of infectious diseases and cancer. The binding of ligands to 
DHFR inhibits the downstream folate pathway that is vital for purine and thymidylate 
synthesis. Trimethoprim (TMP), a clinically used antifolate exhibits resistance in both 
gram-positive and gram-negative bacteria. In this thesis, methods have been refined to 
expedite the synthesis of propargyl linked antifolates for lead optimization.  As a result, 
novel antifolate inhibitors with better pharmacokinetic profile have been designed and 
synthesized for methicillin resistant Staphylococcus aureus (MRSA). Ligands with 
minimal inhibitory concentration (MIC) of 0.3 - 0.6 µg/mL exhibiting an in-vitro half life 
of 60 minutes were achieved. Similarly, to overcome resistance to azole antifungal  
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agents, propargylic linked antifolates exhibiting dual inhibition against Candida albicans 
and Candida glabrata were developed. Antifolate activity of less than 0.1 µg/mL has 
been achieved against the clinically indistinguishable pathogens. In the development of 
antifolates for gram negative bacteria – Escherichia coli and Klebsiella pneumoniae, 
studies were carried out to understand the factors that influence the permeability and 
efflux of the ligands. With a 1,3 benzodioxole moiety of the antifolate exhibiting low 
efflux activity, new leads are in progress to synthesize ligands with potent antibacterial 
activity. 
 In another project, simplified analogs of the natural product, cyclopamine, have 
been synthesized. Cyclopamine inhibits the smoothened (Smo) transmembrane of the 
hedgehog signaling pathway.  The synthesis utilizes a furan based Diels Alder reaction to 
generate a functionalized oxabicyclic adduct. The adduct eventually undergoes a cascade 
reaction involving a tandem ring-opening, ring closing metathesis reaction to generate the 
spirocyclic core of cyclopamine. 
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CHAPTER 1 
INTRODUCTION 
 
Antibiotics – Mechanism of Action and Mode of resistance 
The World Health Organization report of 2012 identifies infectious diseases as 
one of the leading causes of death1 worldwide. Emergence of antibiotic resistance is of 
growing concern, which was forewarned by Alexander Fleming in his Nobel Prize2 
speech of 1945. Though the normal evolutionary process of drug resistance cannot be 
discounted in bacteria, the accelerated rate of resistance is fueled by indiscriminate use of 
antibiotics. According to a report by The New England Journal of Medicine,3 nearly 80% 
of antibiotics in the Unites States are in the argriculture and aquaculture sectors. The 
increase in resistance to antibacterials is compounded by the lack of new class of 
antibiotics since the 1990’s. (Fig.1) 
 
Figure 1 Discovery timeline of antibiotic. Reproduced from Lynn Silver, Clin. Micro.Rev.,2011, 24, 71-109. 
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 A short preview of the anti-bacterials with their mode of action and factors 
influencing their resistance is discussed below. 
1.1 Antibacterial Classification based on Mechanism of Action and Resistance 
 
 Antibiotics can be broadly classified into 3 major classes (Fig.2) based on their 
mode of action. They are inhibition of cell wall synthesis, nucleic acid synthesis and 
protein synthesis. For the inhibition of protein and nucleic acid targets, the antibacterials 
have to permeate the outer membrane and enter the cytoplasm of the bacterial cell.  
 
Figure 2 Mechanism of action of antibiotics Reproduced from http://www.orthobullets.com/basic-
science/9059/antibiotic-classification-and-mechanism 
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1.1.1 Inhibition of Cell Wall synthesis 
1.1.1A β-lactams 
 The bacterial cell wall synthesis occurs in the cytoplasm of the bacteria through a 
series of enzymatic reactions and transported outside as N-acetylmuramyl – pentapeptide 
containing D-alanine-D-alanine chain. For the crosslinking to occur with another 
peptidoglycan chain, the D-alanine is cleaved and the resulting acyl group combines with 
the amino group of a neighboring chain. For the β-lactam antibiotic to effective, it has to 
be recognized by the penicillin binding proteins (PBPs). The recognition results in the 
formation of a stable acyl –enzyme species. The resulting enzyme lactam ester complex 
is resistant to hydrolysis4. This feature of irreversibility of the deacylation step in PBPs 
constitutes the mechanism of action of β-lactams against susceptible strains of pathogens. 
 For a strain to possess a resistance mechanism (Fig.3) to evade β-lactam4, either 
more copies of PBPs exist or the PBPs have evolved to preferentially select for the native 
endogenous peptides than the xenobiotics. Although both processes cannot be discounted, 
it’s the latter that is responsible for evolution of resistance in gram positive bacteria. 
Susceptible strains of Staphylococcus aureus possess four PBPs (PBP1, PBP2, PBP3, 
PBP4), but the PBP2 is the target for β-lactam agents, inhibiting its transpeptidase 
activity. In resistant S.aureus strains an additional PBP2a is present, which crosslinks the 
peptidoglycan layer for the sustenance of the pathogens. The mechanism of methicillin 
resitant S. aureus involves the acquisition of a mecA gene that codes for the PBP2a 
protein. 
 
 
4 
 
 
Figure 3. Mechanism of action by β lactam and vancomycin.  
Reproduced from Nature. 2000, 17, 406(6797):775-81  
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A different kind of mechanism (Fig.4) plays out in the case of gram negative 
bacteria. Here, resistance operates through the acquisition of enzymes called β-
lactamases. The existence of these enzymes predates the large scale use of penicillins. 
The β-lactamases are classified as serine dependent enzymes A,C,D and a metal-based B 
class. They are found in the periplasmic layer of the gram negative bacteria. These 
enzymes hydrolyse the β-lactam ring thereby inactivating the drug. 
 
Figure 4. Mechanism of resistance by β lactamases 
1.1.1B Vancomycin 
The glycopeptide vancomycin inhibits earlier stages of the cell wall synthesis. It 
prevents the growth of peptidoglycan layer by forming a complex with D-alanine-D-
alanine dipeptide through hydrogen bonding. This prevents transglycosylation and 
transpeptidation reactions that are important for building up the peptidoglycan chain.  
The resistance mechanism for vancomycin5,6 operates through the acquisition of a 
plasmid containing van genes (Fig.5) within a transposon.  Courvalin et al proved that the 
five genes van S,R,H,A,X imparted resistance to vancomycin. The vanHAX gene 
encodes a protein to synthesize D-Ala-D-Lac instead of D-Ala-D-Ala. This results in a 
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loss of a single hydrogen bond out of the five with vancomycin leading to 1000 fold loss 
in potency. 
 
Figure 5. Mode of resistance in vancomycin 
Reproduced from Nature. 2000, 17, 406(6797):775-81 
1.1.2 Inhibition of Protein Synthesis 
1.1.2A Aminoglycosides 
 Ribosomes catalyze two chemical transformation namely peptide bond formation 
and ester hydrolysis for polypeptide synthesis. For the initiation of peptide chain, the 30S 
subunit acts as a receptacle for m-RNA and initiator t-RNA. This ensemble for the 
initiation of peptide synthesis is complemented with the docking of the 50S subunit of 
bacterial ribosomes. Aminoglycosides intercept the peptide synthesis process by binding 
to the 30s of ribosomal subunit. More specifically, binding to the subunit-16S7, 8 of rRNA 
interferes with the translation process resulting in defective protein synthesis. 
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Resistance to aminoglycosides can occur in three ways (a) modification of the 
target – rRNA or ribosomal protein, (b) alteration in the transport system of 
aminoglycosides – import and efflux and (c) modification of the ligand by the synthesis 
of aminoglycoside modifying enzymes. The last mode of resistance seems to be prevalent 
in most of the clinical isolates of resistant bacteria. Modification of the target by point 
mutations in the 16S subunit of rRNA is representative of neomycin9 resistance in E.coli, 
while genes for the methylation of 16S rRNA were encoded on transposons10,11 and R-
plasmids on Pseudomonas. The other mode of resistance for aminoglycosides prevalent 
in gram negative bacteria is the efflux pump. 
The most clinically relevant mode of resistance is the enzyme-catalyzed 
modification of aminoglycoside antibiotics.12 The enzymes are group into 3 major 
families (a) aminoglycoside N-acetyltransferases, (b) the aminoglycoside O-
nucleotidylyltransferases and (c) the aminoglycoside O-phophotransferases. As implied 
by the names of these enzymes, they modify the aminoglycoside by acetylation, 
adenylation or phosphorylation of amino or hydroxyl groups. These modifications render 
the antiobiotic incapable of binding to the ribosome. 
1.1.3 Inhibition of Nucleic Acid Synthesis 
1.1.3A Fluoroquinolones 
Bacterial gyrase and DNA topoisomerase IV are enzymes13 that belong to the 
family of topoisomerases II. The two enzymes relieve the strain of the supercoiled DNA 
during replication and transcription. They stabilize the conformation by cleaving both 
strands of the duplex DNA and ligate them together after the uncut ends of DNA slide  
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through the temporary gap. The scissor action14 of the topoisomerase occurs by the 
transesterification reaction of tyrosyl oxygen of the topoisomerase with phosphate of the 
DNA, resulting in a phosphotyrosine link, while the stitching reaction occurs in a reverse 
transesterification reaction between the hydroxyl of DNA and phosphate of the 
topoisomerase. DNA gyrase relaxes the positively or negatively supercoiled DNA and 
topisomerase IV is involved in the catenation and decatenation of daughter DNA. DNA 
gyrase is the enzyme target for fluoroquinolones in the case of gram negative bacteria, 
while topoisomerase IV is inhibited in some gram positive bacteria.  
 
Two major modes of acquisition of drug resistance for fluoroquinolone15,16 exists. 
First is the alteration of drug target – DNA gyrase, more specifically in the Gyr A 
subunit. In E.coli, resistant mutations occur between amino acid residues 67 and 106,  
called the quinolone-resistance determining region (QRDR). These residues reside close 
to the tyrosine amino acid that transiently anchors itself to the DNA during the relaxation 
process. The most common mutations occur with Ser83 and Asp87 residues. The 
mutation Ser83Trp has been shown to reduce the binding affinity of norfloxacin to 
gyrase-DNA complexes. The second mechanism of resitance is by reducing the 
intracellular concentration of quinolones. This is carried out by efflux pumps belonging 
to resistance nodule divison (RND). 
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1.1.3B Folate pathway 
 
The folate metabolic cycle of prokaryotes differs from eukaryotes in the upstream 
process of biosynthesis, while the downstream process overlaps for all species (Fig.6). In 
higher order organisms, folic acid ingested through diet serve as the source of folates, 
while plants, fungi, bacteria and protozoa have an in-built machinery for the de novo 
synthesis of folates. Gene Brown17-24 in 1960 -70 identified the essential enzymes for the 
biosynthesis25 of folate metabolites involved in bacteria. Folates consist of a pterin 
moiety coupled to glutamate residues through a p-aminobenzoate linker. The upstream 
biosynthesis involves the condensation of pABA and 6-hydroxymethyl-7,8-dihydropterin 
pyrophosphate to form 7,8 dihydropteroate catalyzed by dihydropteroate synthase, 
DHPS. The glutamate residue is appended to the pterin benzoate motif by the enzyme 
dihydrofolate synthase, DHFS, to give 7,8-dihydrofolate, DHF. DHF forms the substrate 
for the dihydrofolate reductase, DHFR enzyme to create 7,8 tetrahydrofolate through an 
hydride transfer. In humans, DHF is synthesized directly by hydride transfer to folic acid 
catalyzed by DHFR, while the rest of the folate cycle is akin to the prokaryotes. 
The downstream operations of C1 unit transfer for the synthesis of 
deoxythymidine monophosphate (dTMP), the biosynthesis of purine nucleotides and the 
amino acids histidine and methionine constitute the most important metabolic processes 
of the folate pathway.  
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Figure 6. Folate pathway 
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1.1.3B.1 Clinical Inhibitors of the Folate Pathway 
 
The very first inhibitor of the DHPS enzyme was prontosil (Fig.7) – for which 
Gerhard Domagk was awarded the Nobel Prize in Medicine in 1939. He discovered that 
prontosil was active only in bacterial cells and later research revealed its activity as a 
prodrug. The use of the folate pathway as an antibacterial target was observed by 
Woods26 who carried out experiments with sulfonamides to competitively exclude pABA 
and thereby stall the synthesis of folates. Further research led to the development of 
sulfamethoxazole as a bacteriostatic antibiotic. 
 
Figure 7. Inhibitors of DHPS 
 
DHFR, because of its role in cellular metabolism has become an ideal target of 
antibacterials, antiprotozoal and antineoplastic agents. Nobel laureates George H 
Hitchings and Gerard B. Elion showed the utility of diaminopyrimidine antifolates as 
potent inhibitors of the folate cofactors. Their discovery of 6-mercaptopurine as an 
antineoplastic agent set the tone for a flurry of antifolates – pyrimethamine for protozoal 
infections, trimethoprim as an antibacterial. Later TMP was used in combination with 
sulfamethoxazole to treat methicillin- resistant Staphylococcus aureus (MRSA) and 
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urinary tract infections (UTI) caused by Escherichia coli. Along with cycloguanil and its 
derivatives, these inhibitors belong to the class of non-classical antifolates characterized 
by their lipophilic nature. Methotrexate and aminopterin (Fig.8) - classical antifolates 
bearing resemblance to the natural substrate, folic acid, are potent antineoplastic agents.  
 
 
Figure 8. Inhibitors of DHFR 
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1.1.3B.2 Resistance in Antifolates 
 
 Antifolates are not immune to the evolutionary process of resistance by bacteria. 
The sulfonamide mechanism of resistance is through chromosomal mutation in the dhps 
gene – folP. In a sequence analysis of E.coli mutants, Phe28Ileu and Phe28Leu were 
found to confer resistance to sulfonamide27 while maintaining normal binding to pABA. 
Plasmid mediated resistance was found in the clinical isolates of enteric bacteria that 
enable the pathogens to evade sulfonamides and bind to pABA with a Km of 0.6µM. 
 Use of TMP, chromosomal DHFR undergoes point mutation28 to impart 
resistance in Staphylococcus aureus. The Phe98Tyr mutation in S1 DHFR right below 
the TMP inhibitor competes for hydrogen bonding with the carbonyl of Leu5, which in 
Sa DHFR normally hydrogen bonds with N-4 amine nitrogen of TMP. Another site of 
mutation occurs in the binding site of NADPH with Gly43Ala. Steric induced 
conformational change displaces the NADPH from its native state lowering its affinity in 
the enzyme pocket. This in turn destroys the synergistic affinity of TMP to the active site 
induced by NADPH in Sa DHFR.  
 The rise in resistance for antifolates necessitates the design of new 
pharmacophores to enhance the affinity of ligands in the active site. Research in 
Dr.Wright and Dr. Anderson’s lab pivots around Structure Activity Relationship (SAR) 
based design, synthesis and evaluation of new pharmacophores as antibiotics against 
resistant pathogens. 
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1.1.3B.3 Evolution in the design of Propargyl linked antifoaltes 
 
 TMP as an antibiotic catered only to a subset of pathogenic DHFR enzymes. This 
sowed the seeds for the exploration and optimization of TMP as an antibiotic29 against 
Cryptosporidium hominis and Toxoplasma gondii. TMP inhibits DHFR of C.hominis and 
T.gondii with an IC50 of 14µM and 8µM respectively. Intrigued by the lack of potency, 
refinement was carried out with TMP as the scaffold. The diaminopyrimidine A ring of 
the TMP is retained since it acts as anchor into the active site of DHFR. This interaction 
of pyrimidine ring is conserved across all species. On investigating the crystal structure 
(Fig.9) of Staphylococcus aureus (Sa) DHFR12, TMP forms four hydrogen bonding 
interactions with main chain and side chain residues in the active site. The N1 and N2 
amine of TMP interacts with the oxygen atoms of the Asp27 residue. An additional two 
hydrogen bonds occur between N4 amine and carbonyl oxygen atoms of Leu5 and Phe92. 
Another water mediated hydrogen bond between the  N2 amine and oxygen of Thr111 
lends additional affinity for TMP. Apart from the hydrogen bond interactions,  a number 
of van der Waals interactions with Leu5, Val 6, Ala7, Val31 and Phe92 along with the 
nicotinamide ring of NADPH have been observed. The trimethoxybenzyl group occupies 
a hydrophobic pocket forming van der Waals interactions with the side chain atoms of 
Leu20 and Leu28 on one side and Ile50 and Leu54 on the other. The oxygen atoms of the 
methoxy group do not interact with the enzyme or the cofactor but forms hydrogen bonds 
with water molecules. 
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Figure 9. TMP crystallized with Sa DHFR along with the cofactor NADPH. Reproduced from 
Proteins 2009, 76, 706-717. 
 However comparing the linker of TMP with MTX in the active site, it was evident 
that the trimethoxy benzyl group does not extend as deeply into the hydrophobic pocket 
as observed with the hydrophobic pABA moiety of MTX. A simple strategy to increase 
the affinity of TMP into the active site by increasing the linker length13 of TMP was 
envisioned (Fig.10). The linker length was increased to 2 and 3 carbon atoms between the 
diaminopyrimidine-A and trimethoxy phenyl-B ring. The two carbon linker was 
introduced by an acetylene moiety connecting the two fragments. Further chemical 
modification of acetylene led to cis/trans olefinic substrates and a fully saturated ethylene 
linker. The enzymatic inhibition studies revealed that the two linker strategy suffered 
from entropic and conformational effects. Though the saturated linker provided the ease 
for both aromatic moieties to occupy the active site, the increase in entropy caused by the  
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Figure 10. Generations of Propargyl linked Antifolates
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organization of the highly flexible linker. The other three compounds, though restricted 
by the actylenic and olefinic linkage, are also stricted in their conformations to adopt for 
a productive binding.  
 A balance between conformation and entropy was achieved when a 3 carbon 
linker in the form of a propargyl group was introduced between the two aromatic rings. 
This design enabled the two rings to bind in their respective binding pockets, while 
maintaining the same number of degrees of freedom as in TMP. The propargylic linker 
though did not improve the potency relative to TMP. This was attributed to the loss of 
lipophilic interactions with Leu 25, Leu 33, and Phe 36. This also created a pocket near 
the C6 position of the pyrimidine ring. Further modifications of the propargylic linker 
with substitutions at C6 of the pyrimidine A-ring and at the propargylic position 
engendered a new propargyl linked pharmacophore with potent enzyme inhibition. 
 While the 1st generation compounds with the propargylic linker afforded potent 
compounds, their selectivity over human DHFR was only 36-fold. Continued refinement 
by the addition of a C-ring to the B-ring generated the 2nd generation propargyl linked 
antifolates (Fig.11) with a potency of 1.8 nM for Cryptosporidium hominis and a 
selectivity of 944-fold over human DHFR. The aromatic C-ring was designed so that a 
steric interaction can be tuned to destabilize the interaction with human DHFR while 
maintaining potency against the pathogenic species. The aromatic C-ring projects into the 
lipophilic opening of the active site generating favorable contacts in the pathogen. When 
the 2nd generation ligand was tested against Staphylococcus aureus, it exhibited an 
enzyme potency of 61nM compared to TMP’s IC50 of 23nM.  
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Figure 11. Antibacterial activity of antifolates of different generations 
 
 In order to gain potency against S.aureus organisms, the hydrophobic aromatic C-
ring was changed to a heterocyclic pyridine14 ring30. The crystal structure (Fig.12& 
Fig.13) of a ligand with the heterocycle changed the orientation of the molecule and 
hence its interaction with the side chain residues. The enantiomer of the heterocycle 
ligand that crystallized preferentially was opposite in configuration to that of the 
hydrophobic C-ring. Also the pyridyl nitrogen interacts through hydrogen bonding with 
water molecules at the open end of the active site, contributing to the change in 
orientation of the C-ring. The 3rd generation heterocyclic ligand turned out to be potent 
inhibitor of S.aureus with increased solubility and permeability. 
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Figure 12. 2nd Generation UCP11D35M (blue) crystallized with Sa DHFR along with the 
cofactor NADPH 
 
 
Figure 13. 3rd Generation UCP1006 (green) crystallized with Sa DHFR along with the 
cofactor NADPH 
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1.2 Conclusions 
 
 The different classes of antibiotics exhibit varying modes of resistance. The folate 
pathway is an essential metabolic process for the synthesis of nucleotides and amino 
acids.  TMP targets the DHFR enzyme thereby inhibiting biological processes of the 
folate pathway. Resistance exhibited by TMP has engendered the design and synthesis of 
a new propargyl linked pharmacophore. Generational improvements by ligand 
optimization resulted in a potent inhibitor- UCP1006 for MRSA.  
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CHAPTER 2 
New Synthetic Methodology for Propargyl Linked Antifolates 
Introduction 
Retrosynthetically, propargyl linked antifolates are synthesized in a convergent 
manner by Sonogashira coupling of two fragments – C6-substituted iodo- 
diaminopyrimidine 2 (Scheme.1) and biaryl/ aryl-heteroaryl propargylic alkyne 6. 
Iodinated diamino pyrimidine 2 can be obtained from the tautomer of 3 - amino 
pyrimidinone in 3 steps: (1) by chlorination with POCl3, (2) amination with ammonia in 
methanol and (3) iodination with ICl. The substitution at R1 determines the starting 
precursor for fragment (2).  
 
Scheme 1. Retrosynthesis of propargyl linked antifolates 
For R1 = H, CH3, chlorinated analogs of 3 are commercially available, while for 
the ethyl group at C6 position, amino pyrimidinone 3 can be synthesized by the 
condensation of guanidine carbonate with methyl propionylacetate. The alkyne fragment 
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6 can be accessed through a series of homologation reactions from 7, which is 
synthesized through Suzuki coupling of precursor 8 with suitable boronic acids. 
2.1 Strategies to improve the synthesis of antifolates 
 Currently1, a majority of our analogs are synthesized by changing the C-ring to 
probe for structure activity relatioships. A final step Suzuki coupling to the propargyl 
linked fragment 9, as shown in Scheme 2, would be an ideal situation for screening an 
array of compounds at a rapid pace. But this strategy is limited by the base induced 
cyclization of aminopyrimidine onto the alkyne to form an indole derivative during 
Suzuki coupling. Even if protected amine can be used to prevent cyclization, 
debromination of ring B during palladium catalyzed Sonogashira coupling cannot be 
avoided. 
 
Scheme 2. Suzuki coupling to A B ring system 
 Another strategy to expedite the synthesis of antifolates was to access the 
fragment 6 in an economical way. Currently, the method involves the Suzuki coupling of 
rings B & C, followed by Wittig homologation to get the enol ether as shown in 
Scheme.3. The enol ether was hydrolyzed using either HCl or Hg(OAc)2/KI. The 
resulting aldehyde was homologated by Ohira-Bestmann reagent to give the propargyl 
alkyne.  
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Scheme 3. Synthesis of Propargylic alkyne 
Reactions and Conditions: (a) Pd(PPh3)2Cl2, Cs2CO3, dioxane, 80oC; (b) Ph3P=CHOMe, THF, NaOtBu; (c) 
Hg(OAc)2, KI, THF/H2O; (d) dimethyl(1-diazo-2-oxopropyl)phosphonate, K2CO3, MeOH; (e) 
Pd(PPh3)2Cl2, CuI, Et3N, DMF, 60oC. 
The synthetic protocol above suffered from low yields, especially in the 
hydrolysis and condensation stage. The heterocycle based homologated aldehyde 11 is 
unstable upon exposure to atmospheric oxygen, reverting back to the starting aldehyde/ 
ketone 7. This could be due to enolization of the benzylic position followed by reaction 
with oxygen and cleavage. In the next step of condensation with Ohira Bestmann reagent, 
a base induced isomerization of alkyne to give the thermodynamically stable allene was 
observed. The allene formation was more pronounced with compounds having no 
propargylic methyl (R2 = H). Apart from low yields, the method entails repetitive 
procedure to synthesize compounds with varying substitution at the propargylic position, 
R2 = H, CH3, by starting with an aldehyde or a ketone respectively.  
 To overcome the iterative synthesis, a common precursor that can diverge to give 
substituted propargyl alkynes was required. From the literature, it was evident that 
propargyl alcohol could be the structural motif that can undergo substitution with 
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different nucleophiles. Substitution of alkynol with a hydride (deoxygenation) or a 
methyl nucleophile can engender the required alkynes. 
2.2 Synthetic methodology I 
 Several methods are abound in the literature for the deoxygenation of propargylic 
alcohols. The propargylic alcohol consists of a hard basic site - lone electron pairs on 
oxygen of the alcohol and a soft Lewis basic site – π bonded electrons of alkyne. As a 
result, deoxygenation is catalyzed by bronsted acids, Lewis acids and transition metals. 
 A short account of the deoxygenation methods available in the literature are 
reviewed below. 
2.2a Deoxygenation by Bronsted acids 
 Trifluoroacetic acid2,3 is the most commonly used Bronsted acid for the 
deoxygenation with triethylsilane as the hydride source (Scheme.4). The isomerization 
between the propargyl and allenyl cation tends to decrease the yield of the deoxygenated 
product. The complex with cobalt carbonyl- Nicholas reaction4-6 overcomes this 
limitation by stabilizing the propargyl cation. One of the disadvantages of Bronsted acid 
is over-stoichiometric use to counteract the poor leaving ability of hydroxyl moiety. 
Newer heteropolyacids7 are used catalytically to deoxygenate both the secondary and 
tertiary alcohols. 
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Scheme 4. Deoxygenation by a.Bronsted acid, b. Nicholas conditions, c. heteropolyacids 
2.2b Deoxygenation by Lewis acids 
 Lewis acid - BF3.OEt2 in combination with triethylsilane8 as the hydride source 
has been utilized for the deoxygenation of propargylic alcohols (Scheme.5). Bi(OTf)39, 
Ca(Ntf2)210, InBr311, NaAuCl412 are examples of lewis acids that are available for 
hydrogenolysis. Except for InBr3, all other lewis acid catalyze deoxygenation through a 
carbocationic mechanism. In the case of Indium tribromide, a radical mechanism 
involving Br2In.  was proposed to be involved in the deacetoxylation of propargylic 
acetate. 
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Scheme 5. Deoxygenation by Lewis acids 
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2.2c Deoxygenation by transition metals 
 Ruthenium13,14 and a bimetallic Pd 2+ and SnCl215 are known examples of 
transition metal catalyzed deoxygenation (Scheme.6). A carbocationic intermediate has 
been proposed with the ruthenium catalyst. As a result, substitutions with electron 
withdrawing groups (F, Cl, and CF3) yield little to no product, while with electron 
donating substituents the yields exceed 90%. Moreover, both the transition metals have 
shown to be reactive against secondary propargylic alcohols. 
 
Scheme 6. Deoxygenation by transition metals 
2.2d Deoxygenation for propargyl linked antifolates precursor 
Although a plethora of examples exist for the deoxygenation of aryl propargylic 
alcohols, none of them have a heteroaromatic moiety. The presence of a heterocycle can 
complicate the hydrogenolysis, by complexing with the acids and transition metals. Since 
the antifolates are embedded with heteroaryls, a new methodology was required. The new 
method should be compatible with free or protected TMS alkyne, for which only a few 
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examples exist, as this intermediate will be the precursor for Sonogashira coupling. The 
synthesis of propargylic alcohol was carried out by Suzuki coupling of heteroaryls with 
substituted benzaldehyde derivative (Scheme.7). The alkynol precursor was obtained by a 
nucleophilic addition of ethynyl trimethylsilyl Grignard, generated in situ, to the 
aldehyde.  
 
Scheme 7. Synthesis of Alkynol precursor 
Alkynol of 2’OMe benzaldehyde coupled to pyridine was evaluated for 
deoxygenation under different conditions. With Ca(Ntf2)2 catalyzed reduction, starting 
material was recovered.  Cobalt complex based Nicholas chemistry was carried out next. 
Apart from the extra steps arising from the complexation with cobalt carbonyl, during the 
oxidative removal of the complex with cerium ammonium nitrate, the pyridine heterocyle 
was oxidized. The reduction of the N-oxide added another step to the synthetic scheme 
and the yields suffered. Since the deoxygenated product was obtained using Nicholas 
conditions, optimization of reaction conditions ensued. The reaction was carried out 
without cobalt carbonyl to avoid the unnecessary steps. The reasoning behind this 
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approach was that the 2’ OMe can serve as a carbocation stabilizer. So the alkynol 
precursor was subjected to deoxygenation using BF3.OEt2 and triethylsilane initially at 
0oC followed by heating the reaction mixture to 41oC for 2h. Deoxygenated mixture of 
TMS, TES and free alkyne were obtained. Deprotection of alkyne mixture was carried 
out by hydrolyzing with AgNO3/KCN to give the free alkyne in 74% yield over 2 steps. 
In order to avoid the toxic usage of KCN, the deprotection was also done with an 
equimolar mixture of acetic acid and tetrabutyl ammonium fluoride. Longer reaction time 
with lower yield due to the formation of allene favored the hydrolysis procedure of silver 
nitrate and KCN. 
To understand the versatility of this deoxygenation method, substitutions were 
varied on the top B ring while maintaining pyridine as the C-ring. Table.1. A drop in 
yield for compound 35 was observed compared to 34. This is could be attributed to the 
lack of carbocation stabilization from the 3’OMe. When an additional methoxy group 
was added to 35 as in compound 36 increase in yields were observed. Good yields were 
also obtained when methoxy groups were replaced by dioxolane ring 37. Satisfactory 
results were obtained when the aryl top ring was replaced by an electron rich 
heteroaromatic thiophene ring. The relative low yield was due to the formation of allene 
during the deprotection of TES and TMS alkyne. 
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Table 1. Deoxygenation with Pyridine as the C ring 
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Table 2. Deoxygenation with different heteroaromatics as the C-ring 
Efforts were also directed towards screening for different heteroaromatics on the 
C-ring as shown below in Table.2. Yields ranging from 70-76% were obtained for 
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pyrazine 39, N-methyl imidazole 40 and isoxazole 41. In the case of 42, 43 reduction of 
pyrimidine was observed for the deoxygenated compound in low yields. 
In all of the above examples, a mixture of TES, TMS and a small percentage of 
free alkyne were obtained after the deoxygenation. Though they can be deprotected by 
hydrolysis, this intriguing insertion of triethylsilane is not reported in the literature. 
Further experiments were carried out to understand the mechanism of TES insertion 
during deoxygenation. 
2.2e Mechanistic investigation of TES insertion 
 In order to understand the mechanism of insertion, screening of silane reagents as 
well as Lewis and Bronsted acids were carried out. Bulkier silane reagents – 
trisopropylsilane, triphenylsilane, 1,1,3,3 - tetramethyldisiloxane were screened against 
alkynol 34.  
 
Table 3. Distribution of products of deoxygenation 
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Based on the NMR, relative percentages of alkynes are shown below in Table.3. 
Relative to triethylsilane, a gradual increase in the amount of free alkyne was observed 
except for tetramethyldisiloxane (TMDS) where a majority of deoxygenated compound 
exists as TMS-alkyne. But a mixture of internal alkynes was observed when 1eq of 
TMDS was used.  
 
Table 4. Screening of Lewis acids 
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 Since insertion of the silane reagent was observed even with increased steric bulk, 
except for substituted disiloxane, it became imperative to screen for lewis acids (Table.4). 
It could be postulated that F- or HF was being formed during deoxygenation with 
BF3.OEt2. This could in turn deprotect the TMS alkyne generating an anion. The alkynyl 
anion can react with triethylsilyl cation to give TES alkyne. The Bronsted acid – 
trifluoroacetic acid along with Lewis acids such as MgCl2, B(C6F6)3, AlCl3, Yb(OTf)3, 
silver trifluoroacetate, Zn(OTf)2, ZnBr, InCl3, In(OTf)3 were used for the deoxygenation 
of alkynol 34. 
The screening of lewis acids also gave a mixture of all three products in varying 
proportions. But it also gave a glimpse of tailoring the reaction to specific outcomes. 
When ZnBr is used, deoxygenated internal alkynes could be obtained exclusively, while 
In(OTf)3 provides the the terminal alkyne with a small percentage of allene formation. 
One interesting feature observed with lewis acid screening was that the percentage of 
TES insertion was lower compared to BF3.OEt2 by NMR. It is also worthy to note that 
Br- and Cl- counterions of the lewis acids acts similar to F- in deprotecting the TMS 
alkyne. 
After screening for silane and lewis acids, the only remaining variable is the 
substrate. A simple aryl system 44, 45 (Fig.14) were chosen to study the deoxygenation 
with BF3.OEt2 and triethylsilane.  
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Figure 14. Alkynols without heteroaromatic C-ring 
 
As soon as the BF3.OEt2 was added to the substrate maintained at 0oC, a dark 
brownish black color developed forming a complex. A mild color change normally 
occurs with all of the heteroaromatic substrates 34 - 43, but changes into pale yellow 
color on addition of triethylsilane. Such reversal of color change did not occur with 44 or 
45 even after addition of the reducing agent. NMR revealed neither the presence of 
starting material nor the product. So the experiment was repeated again, but before the 
addition of BF3.OEt2, pyridine was added to the substrate in the ratio of 1:1. The addition 
of Lewis acid did not lead to drastic color change as observed earlier and deoxygenation 
worked efficiently leading to the formation of reduced TES and TMS alkyne. 
It appears that the heteroaromatic moiety plays a dominant role for the 
deoxygenation to take place. Further experiments have to be carried out to elucidate the 
formation of TES internal alkyne and the role of heterocycles in mediating the 
deoxygenation reaction. 
2.3 Alkylation 
 Propargylic alcohols constitute an important structural motif which can undergo 
useful transformations in chemical synthesis. A wide variety of alkylations16 catalyzed by 
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transition metals, Bronsted acids and Lewis acids are summarized here. A novel way to 
generate substituted allene was carried out using allylindium reagents17 and alkylmercury 
halides by radical mechanism.18 Gold catalyzed Friedel crafts based arylation of 
propargylic alcohol 19, allylation, etherification, thiolation with NaAuCl4 20 were 
synthesized by Campagne et al. Studies by Toste et al., on acetylenic alcohols showed 
that rhenium can catalyze addition of amine 21, alcohol 22, heteraromatics like furan, and 
thiophene 23.  Combined catalysis by gold and rhenium24 were utilized for the synthesis 
of diethynes with aldehyde as the starting material. C-, O-, S-, N- based nucleophilic 
addition to the electrophilic propargylic alcohol were catalyzed by BiCl325, Bi(OTf)326, 
FeCl327, InCl328. 
 Nucleophilic addition of 1,3 dicarbonyl derivatives to propargyl alcohols 
catalyzed by FeCl3, Yb(OTf)329, and p-TSA monohydrate30 served as precursors which 
underwent cycloisomerization to substituted furans. p-TSA31 also catalyzed the addition 
of alcohol, sulfur and amine nucleophiles. Copper has been an invaluable catalysts for 
amination32, thiolation33 and allylation.34 Interstingly, copper has been utilized in 
asymmetric addition reactions of amines35,36to propargylic acetates, while Indium (III) 
chloride29 and TiCl437,38 generated a racemate in displacing the ester.  
 Yadav et al., have worked on different catalysts – InBr339, Iodine40, 
phosphomolybdic acid-SiO241, Sc(OTf)342 to understand the propargylic substitution. 
Conversely Nishibayashi et al., made an in-depth study43 of thiolate based ruthenium 
catalysts and exploited its versatility in functionalizing the propargylic alcohol and 
cyclopropyl-2-propyn-1-ols44 with indoles45, aromatics46, ketones47, alcohols, amines, and 
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phosphates. Several reviews48-52 also exist, emphasizing the role of acetylenic carbinols as 
a valuable intermediate in organic synthesis.  
2.3a Methylation 
 In spite of all the references and reviews found in the literature, no single 
procedure has been found for the functionalization of aryl propargyl alcohol with methyl 
as the nucleophile. Macdonald53 et al., evaluated the role of organocopper species with 
propargylic substrates. Soft base – methyl cuprate engendered a wide distribution of 
products consisting of the required substituted acetylene and isomeric allenes. Using 
higher order cuprates, they were able to tilt the distribution in favor of the required 
acetylenic product. Apart from the copper mediated substitution, methylated propargyl 
can be obtained as racemate by deoxygenation of tertiary alcohol10. Enantioselectivity 
was achieved by nickel catalyzed54 Negishi coupling between alkyl substituted 
propargylic halides and aryl zinc. Another cross coupling between substituted tosyl 
hydrozones 55 and trialkylsilylethynes provides alkyl linked propargyl compounds as 
shown in Scheme.8.  
In search of a methyl carbanion to synthesize the propargyl antifolates from a 
common alkynol precursor, Reetz chemistry came to the rescue. Reetz had shown that 
geminal dimethylation of ketones can be done with (CH3)2TiCl256 or sequentially in one 
pot by adding MeLi to the ketone and treating the resultant lithium alcoholide with 
CH3TiCl3.57 Examples also exist for chemoselective methylation of t-alkyl halides with 
methyltitanium (IV) chlorides.58 
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Scheme 8. Synthesis of methylated propargyl alkyne 
2.3b Methylation of propargyl linked antifolate precursor 
It was reasoned that since deoxygenation proceeds through a carbocationic 
intermediate, Reetz chemistry should comply with our substrates. Similar to 
deoxygenation, methylation was performed on the same set of 10 compounds (Table 
5&6) to understand its versatility. 
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Table 5. Methylation with Pyridine as the C-ring 
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Table 6. Methylation with different heteroaromatics as the C-ring 
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 The yields of the methylation reaction varied between 56-66% over two steps 
after deprotection. As expected allene formation was observed in the case of 35 due to 
lack of carbocation stabilization. Thiophene substrate 38 generated allene during the 
deprotection step. 
Thus a very simple procedure for deoxygenation and methylation have been 
devised to achieve a divergent synthesis of substituted propargylic antifolate precursor 
from a common alkynol intermediate.  
2.4 Fluorination 
 In spite of the simplicity of deoxygenation and methylation, both reactions suffer 
from isomerization of alkyne to allene. Thus the reaction is limited only to substrates 
where the intermediate carbocation is stabilized by functional groups on the B-ring. In 
order to overcome the formation of allene, the scope of fluorinating the propargylic 
alcohol was tested. So the strategy was to install either a geminal difluoride at the 
propargylic position or substitute a tertiary alcohol with fluorine as shown in Scheme.9 so 
that the isomerization to allene is arrested. Also the fluorine atoms impart metabolic 
stability to labile sites in ligands and increases the lipophilicity. 
 
Scheme 9. Fluorination using Deoxofluor 
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 Early reports of enantioselective α-fluorination of aldehydes using silylated 
prolinol catalyst was reported by Jorgensen59 et al., while MacMillan60 et al., reported an 
ee of 93-99% with an overall yield of 54-96% using an imidazolidinone catalyst. Since 
the fluorinated aldehdyes are unstable and obtained as the alcohol in the above cases, 
Jorgensen61 group did a one-pot conversion to the alkyne using the Ohira-Bestmann 
homologation procedure. Direct fluorination of enantioenriched tertiary propargylic 
alcohol was carried out by Gree62,63 et al., while Carroll et al., showed that 
enantioenriched fluorides can be obtained from tertiary propargylic alcohols through 
allenyl intermediates.64 Reports also exist for the difluorinated propargyl synthesized by 
Suzuki coupling of aromatic boronic acids with gem-difluoropropargyl bromides.65 
 As a proof of concept, mono fluorination was done on a substrate that underwent 
deoxygenation and methylation. When substrate 37 (Scheme.10) was treated with 
Deoxofluor® mono-fluorinated alkyne was obtained in 60% yield. Another substrate with 
isoxazole as the B-ring 56 isomerizes to 100% allene when Ohira-Bestmann 
homologation route was carried out. This substrate would be an ideal target for 
fluorination on a tertiary alcohol. The fluorinated analog 59 was obtained in 55% yield 
which was subjected to Sonogashira coupling. Both substrates 55 and 59 did not undergo 
Sonogashira coupling. It is quite understandable in the case of 55, since the acidic proton 
can isomerize to allene easily. Optimization of Sonogashira conditions might enable the 
coupling of substrate 59 with iodinated diamino ethylpyrimidine. 
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Scheme 10.Fluorination of 1,3 benzodioxole and isoxazole alkynol 
 
2.5 Synthetic methodology II 
 One important feature of drug discovery program is that the lead compunds 
undergoes a series of refinement to achieve potency, selectivity and also to alleviate 
toxicity. Refinement in terms of functional groups or new ring systems is inevitable. As a 
result the homologation route or the nucleophilic substitution method may not suit certain 
substrates. Newer substrates demand novel synthons for building the molecule or 
synthetic scheme has to be changed depending on the availability of starting materials. 
For the metabolism project, a new difluoro benzodioxolane (Fig.15) as the B-ring 60 was 
required to overcome the CYP inhibition. The commercially available starting materials 
61 & 62 lacks the functionality to attach the C-ring by Suzuki coupling.  
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Figure 15. Diflurodioxolane ligand and available starting material 
 Since further substitution of 61, 62 can give rise to multiple products 66,67 because 
of the pronounced reactivity at postions 4,7 (ortho to difluorodioxolane ring), synthesis of 
difluorinated ring from vanillin was considered the best option. Two methods were 
reported in the literature to synthesize the difluoro compound involving thiocarbonates 
from catechol as the intermediate (Scheme.11). Extremely unstable and difficult to 
handle BrF3 reagent by Rozen68 et al., was not pursued. Instead a milder fluorinating 
agent n-Bu4NH2F3 involving oxidative desulfurization69 and fluorination was attempted 
as shown in Scheme 2.11. Unfortunately the thiocarbonate 66 turned out to be very 
unstable on the column and efforts to do a one pot reaction proved futile. 
 
Scheme 11. Difluorination of thiocarbonate 
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Apart from the lithium mediated functionalization66 of the difluoro 
benzodioxolane, a regiospecific Iridium catalyzed ortho borylation of benzodioxolane70 is 
the other available strategy. It was reasoned that the greater reactivity of 
difluorodioxolane at the ortho position will engender a regiospecific borylation.  From 
the knowledge that sterics, along with electronics, play a dominant role in the 
regiospecificity of Iridium catalyzed C-H activation, it was inferred that substate 62 as 
would be an ideal substrate for C-H activation.  
 
Scheme 12. Functionalization of bromo-1,1difluoro-benzodioxole 
With the doubly functionalized difluorobenzodioxolane, Suzuki coupling was 
attempted with an excess equivalence of 4-bromo-2,6 dimethylpyridine (Scheme.12). 
Quite excitedly, a mono coupled product was obtained with the bromine moiety still 
intact. Similarly, Suzuki coupling was carried out on a benzoxazole derivative 
(Scheme.13), which was borylated by literature procedure.71 
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Scheme 13. Functionalization of benzoxazole 
 With both 64 and 67 available, it was reasoned that lithiation followed by 
nucleophilic addition to 3-(trimethylsilyl)-2-propynal would generate the alkynol 
precursor necessary for deoxygenation and methylation (Scheme.14). But unfortunately, 
with 64 a mixture of ortho lithiated product along with lithium halogen exchange product 
was obtained. With benzoxazole derivative 70 was obtained. Since the previous methods 
of deoxygenation and methylation could not be applied to these substrates, a cross 
coupling strategy was envisioned. 
 Stille coupling72 was carried out for both substrates with vinyl ester 
stannane (Scheme.15) - obtained from Pd catalyzed coupling of tributyltin hydride and 
methyl propiolate.73 The α,β unsaturated ester was subjected to hydrogenation, DIBAL-H 
reduction and Ohira Bestmann homologation to give the propargyl alkyne 73, 74. Allene 
formation was observed with difluoro benzodioxolane, while the isomerization was not 
observed in the case of benzoxazole derivative. 
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Scheme 14. Synthesis of alkynol 
 
Scheme 15. Stille coupling and homologation to propargyl alkyne 
 The reasoning behind choosing vinyl ester stannane as a synthon for installing the 
propargyl alkyne because the method can be altered for enantioselective synthesis of 
propargylic methyl. 
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2.6 Conclusion 
The synthetic protocol of propargylic antifolates by the homologation route was 
limited in its utility for certain substrates. New methods of nucleophilic substitution with 
hydride, a methyl carbanion and a fluoride source was utilized to overcome some of the 
limitations. A stille coupling method was devised for diflurodioxolane and benzimidazole 
substrates to generate the terminal alkyne.  
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CHAPTER 3 
Optimization of Propargyl linked antifolates 
Introduction 
 A series of generational improvements eventually led to lead compound UCP 
1006 and its derivatives. The lead compound1 was based on the design that substitution of 
heteroaromatics as the B ring will impart solubility to the propargylic linked antifolates. 
As a result of the increased hydrophilicity (Table.7), UCP1006 was more potent than the 
hydrophobic biphenyl series by > 60 fold. The next stage of drug development involves 
the investigation of metabolic stability of the lead compounds. The in vitro microsomal 
studies of the lead compounds gave a half-life of 34 and 31 mins, for UCP1006 and UCP 
1021 respectively.  
 
Table 7. Lead compounds for MRSA 
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3.1 Identification of Metbaolites 
 In order to achieve an ideal half – life of 1-2h, the need to identify the metabolites 
of the antifolates became imminent. Zhou2 et al., carried out an in vitro studies by 
incubating UCP1006 (Scheme 3.1) with mouse liver microsomes in the presence of 
NADPH for one hour. The metabolites of the compound was identified and characterized 
by LC-MS.  
 
Scheme 16. Metabolites of UCP 1006 
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The two major metabolites of UCP1006 are the N-oxidation of pyridine and 
demethylation accounting for 74% of all the metabolites. The remaining two metatolites 
are the N-oxidation of pyrimidinyl nitrogen (isomers) and the oxidation on the pyrimdine 
A-ring, ambiguously assigned as the C-6 oxidation at the benzylic position. It has been 
shown that propargyl methyl and the position of methoxy group have an effect on half-
life and N-oxidation of pyridine ring. The presence of branching at the propargylic 
position with a methyl group increased the half-life and decreased the relative abundance 
of the pyridyl-N-oxide. Also shifting the methoxy from 3’ to 2’ position on the B-ring 
increases the half-life by decreasing the oxidation products of the amino pyrimidine A-
ring. When a hybrid inhibitor was formed by combining the above two features – 
UCP1040, the half-life of the compound increased to 65 mins (Table.7) 
 
Table 8. Antibacterial and in-vitro metabolic profile of UCP1040 
 
Though the half-life has been increased with UCP1040, CYP inhibition is in the 
low nanomolar range for CYP3A4, as is also the case with UCP1006 and UCP1021. The 
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cytochrome P450 play a major role in the elimination of xenobiotics. CYP3A4, CYP2D6, 
and CYP2C9 constitute the major isoforms responsible for metabolism of pharmaceutical 
ligands. Inhibiting the CYPs can lead to drug-drug interactions and hence pose the risk of 
exposure to high concentrations of drug or formation of reactive intermediates leading to 
toxicity. The heterocyclic compounds – pyridine, imidazole are classified as type II 
ligands3. They interact with the heme of CYP450 through the lone pair of electrons on the 
nitrogen forming reversible inhibitor complexes. This inhibition can influence the half-
life of the antifolates generating an artificially long t1/2.  
In order to be certain about the half-life value of UCP1040, the microsomal 
studies were carried out at a lower concentration (0.5µg/mL) of the ligand (Table.8). 
Unfortunately, the t1/2 turned out to be 7 mins as against the 65 mins seen at a higher 
concentration (5µg/mL). Hence, optimization of lead compounds became necessary to 
overcome CYP inhibition and increase the half-life. 
 
3.2 Minimizing CYP Inhibition 
 The strategies to overcome CYP inhibition involve reducing the pKa of the 
heterocycle or by increasing the sterics around the nitrogen of pyridine. UCP1040 was 
taken as the template by retaining the top B-ring and changing the bottom C-ring. 
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3.2.1 Changing the C-ring 
 
Table 9. Changing the C-ring 
 Reduction of pKa of the pyridine can be accomplished by introducing another 
nitrogen moiety into the pyridine rings. This was carried out by substituting the C-ring 
for pyrimidine, pyrazine, pyridone and an isoxazole heterocycle (Table.9). 
Compared to the pKa of pyridine ~ 5.2, the pKa of pyrazine and pyrimidine are 
around 0.6 and 1.3 respectively. While the antibacterial activity of UCP1066, UCP1067, 
UCP1085 have been maintained, great improvements in reducing the CYP inhibition 
occurred with the isoxazole ring.  The pyrimidine, pyrazine and pyridone moieties show 
reduced inhibition of CYP2D6 while maintaining the inhibition of CYP3A4. The 
synthesis of the compounds followed method B, with a slight modification for pyridone.  
Since the boronic acid of pyridone was not commercially available, the acid 
hydrolysis of 2 methoxy pyridine or diazotization reaction of 2-amino pyridine4 were the 
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options available to access the pyridone. The commercially available 2-amino-4-bromo 
pyridine was subjected to diazotization (Scheme.17). Since the pyridone moiety has the 
propensity to form ligands with palladium catalysts, it necessitated the protection of N-
pyridone. The pyridones are normally protected with benzyl group, but the presence of an 
alkyne moiety in the antifolate ligands precluded its use. Since the attempts to protect 
with a Boc group also failed, it was decided that acid hydrolysis of 2-methoxy pyridine 
after the final Sonogshira coupling could be employed. 
 
Scheme 17. Pyridone synthesis 
The deprotection of 2 methoxy pyridine was carried out using BBr3 (Scheme.18). 
The presence of 2’OMe in the B ring complicated the deprotection. NOESY experiments 
revealed that BBr3 deprotected the top ring rather than methoxy next to pyridine. 
Increasing the equivalence of BBr3 did not result in the formation of pyridone, since the 
deprotection of 2’OMe of the top B-ring resulted in precipitation of adduct. 
 
Scheme 18. Demethylation of UCP1077 
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A literature procedure5 was found in which the deprotection of methoxy next to a 
heterocycle can be chemoselectively (Scheme.19) cleaved in the presence of other 
methoxy groups. Several byproducts coupled with increased polarity of the molecule 
necessitated an HPLC based separation with a 10% yield. 
 
Scheme 19. Chemoselective demethylation of UCP1077 
 
 Although UCP1085 with the isoxazole ring provided reduced CYP inhibition, the 
effect of sterics next to the pyridine nitrogen in reducing the CYP inhibition was also 
explored. 
3.2.2 Steric Inhindrance around the pyridyl nitrogen 
 There are two ways of increasing the steric hindrance around the pyridine 
nitrogen. First method involves the substitution next to the pyridine and the other method 
is to move the nitrogen either a) ortho6 to the biaryl linkage so that ring B can provide the 
necessary steric hindrance or b) flipping the two rings B&C so that pyridine now 
becomes B-ring (Table.10).  
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Table 10. Changing the position of pyridyl nitrogen 
Both compounds UCP1071 and UCP1047 did not show any reduction with the 
CYP3A4 inhibition. While antibacterial activity was maintained with UCP1071, it was 
lost with flipped pyridine ring- UCP1047. Possible reasons for the loss of activity with 
UCP1047 could be due to electronegative pyridine on the top ring and also substantial 
loss of solubility.  The other strategy to increase the steric bulk around pyridyl nitrogen 
by ortho substitution was carried out.  The UCP1040 was substituted with a methoxy and 
2,6 dimethyl next to the pyridine. The sterically hindered pyridines – UCP1076, 
UCP1077 (Table.11) seem to have better potency than UCP1040 at 0.15µg/mL. Lowered 
CYP inhibition relative to UCP1040 was also observed for both the analogs.  
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Table 11. Sterics around the pyridyl nitrogen 
 
UCP1085 with the isoxazole ring and the sterically hindered pyridine analogs 
engendered reduced CYP inhibition. But still the half-life is very low at 8 mins for 
UCP1076. It could be argued that reduced half-life can arise from the demethylation of 
the 2’OMe of the B-ring.  
3.3 Increasing Half-life 
 In order to synthesize analogs to increase the half-life, sterically hindered 
dimethylpyridine was chosen as the C-ring because of its potency compared to isoxazole 
and ease of its boronate ester synthesis7. Two routes of modification were planned for the 
top B-ring. One method involves variation of methoxy functionality and the second 
method involves replacing the methoxy with a different functional group. 
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3.3.1. Variations of O-Methoxy 
 The two common analogs to replace the methoxy group are the deuterated8 and 
trifluoromethoxy groups. Both the analogs were proposed to slow down the rate of 
demethylation.  
 
Table 12. Varying the methoxy group in B-ring 
From the comparative table.12 above, it is evident that trifluoromethoxy has 
increased the half-life to 62 mins with minimal CYP inhibition. In terms of potency there 
is a 2-4 fold loss as the transition is made from a hydrogen bond donor (OCH3) to a 
hydrogen bond acceptor (OCF3).  Substitution with OCD3 had no effect on slowing down 
the rate of demethylation as evident from the low half-life values. With the fluorine of 
OCF3 and dimethyl of pyridine, the hydrophobicity of the ligand has been increased. In 
order to further refine UCP1129, the need of methyl group at the propargylic position 
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and the effect of a single methyl around pyridine were probed. Quite satisfactorily, 
UCP1125 without the propargylic methyl maintained the low inhibitory (Table.13) effect 
on CYPs while having a two fold increase in potency. This follows the pattern for MRSA 
in which compounds without the propargylic methyl are more potent. But the increased 
flexibility of the ligand has increased its CYP3A4 inhibition slightly, though within 
permissible limits. Similarly a single methyl around pyridine in UCP1126 is well 
tolerated and does not show any CYP inhibitory activity. Based on the half-life data, it 
will prudent to further refine UCP1126 by removing the propargylic methyl and hence 
reducing the lipophilicity of the molecule further. 
 
 
Table 13. Optimization of UCP1076 
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3.3.2. Changing substituents at 2’position of B-ring 
To further probe the role of 2’OMe, substituents –H, Cl and –F at 3’position were 
studied (Table.14). No substitution at 2’ position had an effect on increasing the potency 
of the ligand. The half-life though not optimal, has increased from 8 to 20 mins relative to 
UCP1076. The increase in half-life suggests that the rate of hydroxylation by CYP 
enzymes is slower than the rate of demethylation for the propargyl linked antifolates. In 
order to block the sites of hydroxylation, Cl was substituted at the 2’ position and F at 3’ 
position. A better half –life and reduced CYP inhibition was achieved for the chlorine 
analog, while the fluorine ligand shows inhibitory activity for CYP3A4 at 5.3 µg/mL. 
 
 
Table 14. Optimizing B-ring for potency 
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3.3.3. Blocking sites on the B-ring 
 From the above analogs, it became evident that the 2’methoxy is not required for 
maintaining the potency of ligands against MRSA. So the top ring was further probed for 
activity and pharmacokinetic behavior. To block the potential site of hydroxylation, a 
dioxolane ring was appended to the B-ring (Table.15). Since the benzodioxolane is a new 
pharmacophore, its potency was first tested with pyridine as the C-ring. Three new 
analogs were synthesized bearing a dioxolane ring at 2,3 and 3,4 positions. 
 
Table 15. 1,3 benzodioxole as the B ring 
 The new pharmacophore seems to maintain enzyme inhibition and good potency 
against MRSA. In the dioxolane series, UCP1038 exhibits potency similar to UCP1006. 
Again CYP inhibition are at an alarming low nanomolar levels and the half- life at 
5µg/mL concentration is caused by pyridine. When the metabolite identification was 
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carried out, no metabolites were found. This is could be due to the Mechanism Based 
Inactivation9 (MBI) of CYP enzymes. 1,3 benzodioxole moieties fall under the category 
of quasi-irreversible inactivators of CYP enzymes (Scheme.20). The reactive species of 
the benzodioxole bind to the heme of the CYP in a tight non-covalent interaction. Two 
paths can diverge from hydroxymethylene intermediate leading to carbene and catechol 
as shown below. In the case of UCP1038, it might be going through a carbene 
intermediate and forming an irreversible complex with the heme of the cytochrome. This 
could explain the lack of metabolite formation seen with dioxolane ligands.  
 
Scheme 20. Mechanism based inactivation of 1,3 benzodioxole moiety 
 
Paroxetine by Concert pharmaceuticals 10 has a dioxolane moiety which 
undergoes carbene complex formation catalyzed by CYP2D6. CYP inhibition was 
reduced by slowing down the rate of carebene formation by deuteration of dioxolane 
moiety (Fig.16). 
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Figure 16. Deuterated paroxetine 
Since the CYP numbers for both isoforms of UCP1038 were very low, it was 
decided to employ the same strategy of deuteration. Deuterated iodomethane 
(Scheme.21) was used to synthesize 11,12 UCP1070 and UCP1112. 
 
Scheme 21. Synthesis of deuterated dioxolane 
 
Table 16. Deuterated UCP1070 
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 The effect of deuterium in reducing the CYP inhibition was not observed with 
UCP1070 (Table.16). No improvements was seen in CYP2D6 as detected in the case of 
paroxetine. Only advantage of switching to d-dioxolane was the detection of metabolite 
formation by LC-MS. Though not quite proven without ambiguity, the metabolite 
appears to be formation of catechol. The CYP inhibition seen even with d-dioxolane 
could still be arising from the pyridine. Hence, to differentiate the effect of d-dioxolane 
from the H-dioxolane, the CYP inhibition by the pyridine moiety has to be stalled. So 
UCP1112 (Table.17) was synthesized with dimethylpyridine as the C-ring. To further 
exploit the potency of bicyclic structures on the B-ring, bioisosteres of dioxolane were 
synthesized. 
 
Table 17. Isosteres of 1,3 benzodioxole 
 Comparing UCP1112 with UCP1070, potent CYP inhibition was still observed, 
except that the isoforms being inhibited extensively are reversed. A two-fold loss in 
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potency was observed with 2,6 lutidine as the C-ring. UCP1114 analog shows moderate 
CYP inhibition relative to the dioxolane series, but suffers from rapid biotransformation 
by the microsomes. The low half-life value reflects the microsomal instability of 2’ or 3’ 
methoxy analogs. 
 To capitalize on the antibacterial activity of dioxolanes, a fluorinated analog13 was 
conceived. Similar to OCF3, it was hypothesized that the substitution of electronegative 
fluorine in the dioxolane moiety would overcome the CYP inhibition and low metabolic 
profile. Since it was anticipated that the fluorinated analog might increase the 
lipophilicity of the ligand, another bicyclic B-ring – benzimidazole was synthesized 
(Fig.17). It will be an interesting study to explore the effect of a restricted benzimidazole 
moiety on the antibacterial activity and enzyme inhibition. 
 
Figure 17. Fluorinated 1,3 benzodioxole and benzimidazole 
3.4 Enzyme selectivity over human-DHFR 
While improving the metabolic profile of propargyl linked antifolates, efforts 
were also directed towards gaining selectivity over human DHFR.  Though the function 
of DHFR is conserved in evolutionary processes, small amino acid residue differences 
across species are exploited to achieve selective and potent antifolates. A study on the 
effect of propargyl linked antifolates towards the loop region in the active site revealed a  
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Figure 18. Crystal structures of UCP1006 in bacterial (green) and human (yellow) DHFR 
 
 
 
83 
 
ligand dependent conformational change that is prevalent across species14. The crystal 
structures of UCP1006 with h-DHFR revealed that interaction between the inhibitor and 
residues Phe 31, Phe 34 and Asn 64 increases the potency for h-DHFR.  
Comparing the crystal structures of UCP1006 with bacterial and human DHFR 
(Fig.18), shows that the pyridine C-ring tends to adopt a perpendicular conformation with 
the B-ring in pathogenic DHFR while adopting a planar conformation with h-DHFR. To 
gain selectivity, a design wherein a methyl15 group in the C-ring ortho to the biaryl 
linkage was conceived. The intended effect was to force the C-ring to adopt a 
perpendicular conformation thereby reducing its hydrophobic interaction with the Phe 31 
and Phe 34 of h-DHFR. 
 
Table 18. Optimization for human selectivity 
 The newly designed UCP1075 gave a 16-fold increase (Table.18) in selectivity 
compared to UCP1040 while maintaining antibacterial activity at 0.3µg/mL. 
 
 
84 
 
3.5 Conclusions 
Optimization of propargyl linked antifolates was carried out to overcome CYP 
inhibition, improve half-life and selectivity over human DHFR. The pyridine C-ring was 
replaced by isoxazole and 2,6 lutidine to overcome CYP inhibition. The B-ring was 
switched from methoxy to trifluoromethoxy to prevent demethylation and increase the 
half-life from 7 to >60 mins. Further changes in the B-ring were explored with 
benzodioxolane, d-benzodioxolane, fluorinated –benzodioxolane, benzodioxane and 
benzimidazole to gain potency and metabolic stability. Selectivity over human DHFR 
was also achieved with UCP1075.  
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CHAPTER 4 
Dual Inhibitors of Candida albicans and Candida glabrata 
 
Introduction 
 Candida species constitute the fourth leading cause of blood stream infections 
after bacterial pathogens.1-3 Of the Candida species, glabrata and albicans contribute to 
increasing prevalence of candidemia. While C.albicans remain susceptible to azoles, 
flucytosine and echinocandins, C.glabrata is losing its potency against azoles and gaining 
resistance to echinocandins.4-6 This resistance necessitates the need for dual inhibition of 
both species since they are clinically indistinguishable from each other. Similar to the 
propargyl linked antifolates developed for MRSA, antifolates for the fungal species had 
undergone generational improvements (Table.19). The biaryl lead compound UCP10237,8 
had good enzyme inhibition for C.albicans and C.glabrata at IC50 values of 30, 28nM 
respectively. Introduction of a heteroaromatic ring to increase the solubility of UCP10069 
exhibited better antifungal activity compared to the hydrophobic UCP1023 but does not 
correlate with the enzyme inhibition.  
 Lack of correlation between enyme inhibition and antifungal activity were also 
observed for C.albicans by two other research groups. Research by Glaxo10 concluded 
the absence of relationship between activity and inhibitor size or hydrophobicity. 
Similarly a German company11 also could not explain the lack of correlation after 
invalidating the role of efflux pumps. They speculated that the permeability of 
compounds against cell membranes might explain inconsistencies between IC50 and MIC. 
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Table 19. Antifungal activity of propargyl linked antifolates 
   
4.1 Dual Inhibitors for C.glabrata and C.albicans 
 In search of different chemotypes that might enable dual inhibition of both species 
of Candida, screening was performed on the library of propargyl linked antifolates. 
Interestingly, para isomers (Table.20) seem to exhibit dual inhibition with inconsistent 
enzyme inhibition as observed previously in literature.  
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Table 20. Antifungal activity of para isomers 
 Apart from the enzyme inhibition – which is a good predictor for in vitro activity, 
the shape of the molecule also seems to influence the antifungal activity. To gain further 
understanding into the role of para isomers and their interaction with the active site, 
crystal structures of UCP111H with DHFR were grown in both species by Dr. Paulsen.  
4.1.1 Crystal Structures of UCP111H with Candida glabrata and C.albicans 
 Crystallization with the racemate of UCP111H showed two molecules of the 
protein complexes in the asymmetric unit for the R enantiomer (Fig.19). The two 
molecules adopt different conformation in the active site. The difference lies in the 
orientation of the 3’methoxy. In one conformation, 3’OMe points down into the pocket 
enclosed by Phe 36, Leu 69 and Met 33 and the other points the methoxy toward Ser 61 
to form a water mediated hydrogen bond. Except for the 3`OMe, all other interactions are 
conserved including the hydrogen bonds and hydrophobic interactions between the 
pyrimidine ring and Glu 32, Ile 9, Phe 36, Met/Ile 33 and Ile 121. The propargyl linker 
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forms van der Waals interactions with Ile 121 and Leu 25 as well as NADPH. The 
biphenyl moiety forms important hydrophobic contacts with Ile 62, Pro 63, and Phe 66. 
When UCP111H was co-crystallized with C.albicans DHFR, a conformation wherein 
3’OMe was oriented towards Phe 36, Leu 69 and Met 33 was observed at 100% 
occupancy. 
 
 
 
Figure 19. UCP111H crystalized with Cg DHFR in two conformations, b. Overlay of 
UCP111H and UCP111E in Ca DHFR 
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 From the crystal structures of both species, it is evident that the ring C can be 
probed for better inhibition and potency without altering the conformations of the ligand. 
4.1.2 SAR studies of para-linked antifolates 
 Using UCP111H as our lead compound, the C-ring was changed to reflect a 
variation in cLogP values. Ester, alcohol, carbamate, tolyl, pyridine, cyano derivatives 
were synthesized starting with the bromoketone1. Various boronic acids were coupled 
utilizing Suzuki coupling conditions (Scheme.22). Following the earlier route of Wittig, 
acid hydrolysis, Ohira Bestmann homologation and Sonogashira coupling the propargyl 
linked antifolates were obtained. Biological evaluation of these compounds show that the 
changes in the C-ring are well tolerated with the IC50 values of Cg DHFR varying 
between 6-31nm and for Ca DHFR aroung 18-64nM. Interestingly, compounds with 
lipophilic substitutions at C-ring  
 
 
Scheme 22. Synthesis of para isomers of propargyl linked antifolates 
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exhibit significant antifungal activity against C.albicans with MIC values ranging from 
1.8 – 7.5 µg/mL. Apart from the shape of the molecule, the hydrophobicity of the C-ring 
also influences the antifungal activity against C.albicans.  
 
Table 21. Polar substituents in the C ring 
The SAR studies also reveal two clusters of activity. In the first cluster of 
compounds with substituents NMe2, endo-N, OH and CO2NH2, (Table.21) a significant 
differences in activity between the two species were observed. The compounds exhibited 
reasonable antifungal activity with C.glabrata but almost little to no activity was 
observed in the case of C. albicans, with an exception of heteroaromatic substituent 
UCP1044. Some pyridine and pyrimidine compounds were shown to exhibit antifungal 
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activity in efflux knockout strains12 of Candida albicans. Their mechanism of action 
involves the inhibition of lanestrol demethylase of the pathogenic C. albicans. 
In the second cluster of compounds consisting of hydrophobic and electron 
withdrawing groups, (Table.22) activity is maintained in both species.  
 
Table 22. Hydrophobic and electron withdrawing substituents 
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The hydrophobic phenyl and tolyl derivatives – UCP1043 and UCP1046 exhibit 
antifungal activity against C.glabrata that is relatively similar to the heteroaromatic 
derivative UCP1044 belonging to the polar cluster. They suffer from a 6 fold loss in 
activity when electron withdrawing groups are substituted in the C-ring. Interestingly, no 
such drastic loss in activity is observed between hydrophobic and electron withdrawing 
substituents with C.albicans except in the case of ester derivative UCP1059. One of the 
drawbacks with the second cluster of molecules, which exhibit antifungal activity, is that 
their hydrophobic nature reduces the solubility of these ligands. 
4.1.3 Case of META vs PARA substitution 
A comparison of isomeric structures of the ligands depicts that the shape of the 
molecule influences the antifungal activity of both species of Candida. (Table.23) 
 
Table 23. Comparison of META vs PARA isomer 
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  The para isomer seems to influence the penetrating ability of these propargyl 
linked antifolates. The permeability barrier of meta isomers was proven experimentally 
with Triton X-100 studies. Triton X- 10013 is known to increase the membrane 
permeability without denaturation. When UCP1023 or UCP1044 were treated with 
0.01% Triton X-100, the potency of the meta compounds were increased. 
4.2 Lead Design and Synthesis for Dual Inhibition 
 The para compounds having dual inhibition are lipophilic in nature. UCP1043 
exhibited water solubility at 0.25 µg/mL in the presence of 0.02% hydroxypropyl 
cellulose.  
 
Table 24. Lead compounds with heterocyclic B-ring 
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To increase solubility, heteroaromatic rings (Table.24) can be incorporated into 
the ligands. From the SAR studies, it is evident that the C-ring has to be hydrophobic. So 
lead compounds were synthesized by changing the B-ring to pyridine and pyrimidine. A 
striking improvement in antifungal activity against both species (MIC = 0.2 – 0.78 
µg/mL) was obtained. Triton X-100 experiments with UCP1052 did not alter the 
antifungal activity. Compared to distal pyridines, incorporation of pyridine14 in the B-ring 
did not improve the solubility of the compounds. But with the pyrimidine as the B-ring, 
solubility of 60 µg/mL was achieved. 
4.3 Conclusions 
 The meta isomer of propargyl linked antifolates exhibit antifungal activity against 
Candida glabrata, while the para isomer has dual inbition for both species. Hydrophobic 
C-rings enhance the dual inhibition relative to the polar substitutions. Better enzyme 
inhibition and antifungal activity were achieved with pyridine and pyrimidine as the B-
ring. The heterocyclic series also displayed better selectivity over h-DHFR along with 
improved solubility as in the case of UCP1055. 
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CHAPTER 5 
Antifolates for gram negative pathogens 
 
Introduction 
 Resistance of antibiotics to gram negative pathogens is increasing at an alarming 
rate. The gram negative bacteria differ from the gram positive species by their specialized 
outer membrane. This is one of the manifestations of an intrinsic resistance apart from the 
efflux pumps. Intrinsic resistance is not brought about by drug pressure or horizontal 
gene transfer.  
5.1 Outer membrane of gram negative species 
In addition to the peptidoglycan layer – a constituent of gram positive bacteria, 
the gram negative species has an asymmetric bi-layered1 outer membrane (Fig.20). It is 
made up of an outer leaflet of lipopolysaccharides (LPS) and an inner leaflet of 
phospholipids (PL).  
 
Figure 20. Outermembrane of gram negative bacteria 
Reproduced from Nat Rev Micro 2009, 7, 677-683 
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The LPS layer consists2 of three domains – (1) lipid A connected to the (2) core 
oligosaccharide which is linked to (3) long polysaccharide - O-antigen (Fig.21). This 
layered arrangement makes it amphiphilic carrying a net negative charge. The fatty acid 
chain of the lipid A region acts as a secondary barrier to hydrophobic molecules. The 
saturated lipid chains originating from a single head group, and the phosphate groups are 
held together laterally by Mg2+  
 
Figure 21. LPS layer of E.coli. Reproduced from Nat Rev Micro 2009, 7, 677-683 
 
and Ca2+ ions3 enabling it to pack tightly and hence reduce fluidity. This prevents the 
hydrophobic molecules from partitioning into the inner core of the LPS layer and thereby 
slowing down the diffusion of lipophilic molecules into the cytoplasm. The membrane 
permeability also acts as a barrier for the pathogens to accumulate nutrients. They 
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overcome the permeability by having small outer membrane proteins called porins. 
Though the porins can serve as a conduit for hydrophilic antibiotics, then act as sieves 
filtering out drug molecules based on size4, charge5 and hydrophobicity. In response to 
influx of hydrophilic antibiotics, porins undergo mutation6 differing in pore size, quantity 
and channel blockers, imparting resistance.  
5.2 Efflux pumps 
 Another mode of intrinsic resistance exhibited by pathogenic bacteria is the 
presence of efflux pumps. Efflux pumps7,8,9 tend to flush out the antibiotics utilizing a 
complex assembly of transporters.  
 
Figure 22. Different classes of efflux pumps. Reproduced from Clin. Microbio.Rev. 2006, 19, 382 
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Efflux reduces the accumulation of exogenous ligands inside the cell and thereby 
increases the survival of the pathogens. The efflux pumps can be encoded genetically or 
acquired through plasmids. Five families of efflux systems have been found: (Fig.22) (1) 
multidrug and toxic compound extrusion (MATE), (2) major facilitator superfamily 
(MFS), (3) staphylococcal multiresistance (SMR), (4) resistance nodulation divison 
(RND) and (5) ATP binding cassette (ABC) transporters. 
The resistance nodulation division (RND) constitute major efflux systems 
imparting resistance and virulence to Escherichia coli and Klebsiella pneumoniae. The 
RND efflux pump is a tripartite system consisting of AcrA in the periplasmic space, 
AcrB in the cytoplasm region and TolC in the outer membrane. All the three components 
assemble together to pump out the antibiotics.  The RND pumps use proton motive force 
(PMF) to establish efflux along a concentration gradient. They are also known as proton 
antiporters, exchanging one H+ for one drug molecule.  The RND efflux pump specificity 
is very broad extruding cationic, neutral and anionic species very efficiently. In order to 
overcome the efflux pump, two strategies can be employed – (1) design of antibiotics that 
are not substrates for the pump, (2) design of efflux pump inhibitors (EPI) 10 that can 
potentiate the activity of existing antibiotics. The examples of existing EPI (Fig 5.4) 
include phenylalanyl arginyl –β napthylamide (PAβN) 11, carbonyl cyanide m-
chloropheylhydrazone (CCCP), quinolones and arylpiperzines. PAβN has been 
implicated to permeabilize the membrane at certain concentrations.12None of the EPI 
have been approved for clinical use yet.  
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Figure 23. Efflux pump inhibitors 
5.3 DHFR as drug target for gram negative pathogens 
 DHFR is a validated drug target for the treatment of gram negative infections. 
Trimethoprim-sulfamethaoxazole (TMP-SMX Bactrim) targeting the DHFR and 
dihydropteroate synthase DHPS enzymes is the only choice of clinically approved drugs 
of the folate pathway. A slow rise in resistance is observed for TMP-SMX13-15 in 
Enterobacteriaceae strains. Resistance is normally acquired through the acquisition16-18 of 
TMP-insensitive DHFR. This necessitated the need for potent compounds to overcome 
resistance. 
5.3.1. Screening of antifolate libraries 
Initially, existing library of compounds (Table.25) were screened to assess the 
potency and inhibition of antifolates for both Klebsiella pneumoniae and Escherichia 
coli. 
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Table 25. Screening of antifolate library of compounds 
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Table 26. Influence of para isomers for antibacterial activity 
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It is evident from the comparison of UCP1113D5M and UCP1006 that the 
heterocyclic moiety has better potency than the hydrophobic analog. Also the 
heteroaromatic analog exhibits a 10-fold greater potency over the saturated heterocycle 
UCP1003. UCP1038 with the benzodioxole moiety shows good potency against 
K.pneumoniae and E.coli compared to other antifolate analogs except TMP, in spite of its 
low nanomolar enzyme inhibition of K.pneumoniae.  
The other chemotype – para isomers of antifolates (Table.26), were also screened 
to see if they exhibit the membrane permeabilizing effect as observed with fungal 
pathogens. Similar to the meta isomer, the hydrophobic C-ring is not well tolerated. An 
interesting feature of para isomers is that the MIC values for both species are relatively 
close, compared to the meta isomer. 
5.4 New inhibitors of antifolates for gram negative pathogens 
 Based on the screening, compounds were designed to utilize both chemotypes of 
meta and para isomer. Both the isomers were substituted with hydrophilic groups in the B 
and C-ring to exploit the presence of porins. Synthesis of compounds were carried out 
using the procedures described in chapter 2. 
5.4.1 Para isomers 
 In the para series, the B-ring was switched to pyridine and pyrimidine (Table.27). 
The bottom C -ring was substituted with pyridine and piperazine to increase the polarity 
of the compounds. UCP1087 with the piperazine C-ring was not active, consistent with 
the screening results. The para bipyridine analog showed good potency and enzyme 
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inhibiton against Kp but the activity did not translate to clinical strains with MIC values 
>50. Its activity was potentiated by the use of PaβN exhibiting a MIC value of 0.781 
µg/mL, suggesting permeability or efflux issues.  
 
Table 27. Antibacterial activity of polar para compounds 
5.4.2 Meta isomers 
 Since the para isomers were exhibiting possible efflux activity, meta isomers were 
synthesized by changing the C-ring to more polar groups (Table.28). The anisole as the 
top B-ring was selected to impart hydrophobicity to the ligand, as the more hydrophilic 
ligands were extruded. When the C-ring was substituted with aminopyrimidine, activity 
of 1.25 µg/mL was achieved in the test strain, but these compounds lacked potency with 
the clinically resistant strain.  
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Table 28. Antibacterial activity of polar meta compounds 
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Another approach to increase the polarity of the C-ring was to reduce the ring size 
to 5-membered heteroaromatics. N-methylimidazole with a pKa of ~7 was chosen as the 
C-ring. UCP1084 was potent against the test strain and also exhibited a reasonable 
potency against the clinical strains relative to other analogs. SAR was performed on 
UCP1084 by removing some of the methyl groups to understand the effect on efflux. 
Though UCP1091 without the propargylic methyl had the lowest fold change in terms of 
efflux activity, it lost its potency against the clinical strain. UCP1092 and UCP1101 were 
similar in activity to UCP1090. The efflux activity has been a recurring issue with both 
meta and para isomers. The benzodioxole scaffold UCP1038 that exhibited potent 
activity against the test strain was screened against the resistant pathogenic strains. 
UCP1038 turned out to be the best lead compound (Table.29) against the clinical 
isolates. 
 
Table 29. Influence of 1,3 benzodioxole on clinical isolates 
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5.4.3. Dioxolane series 
 Efforts were directed towards synthesizing more analogs of the dioxolane series 
to gain an understanding of the efflux pumps. Benzodioxole have been shown to exhibit 
efflux pump inhibitory activity against NOR efflux pumps of Staphylococcus aureus. 
With benzodioxole as the B-ring, the C-ring was substituted with heterocycles of varying 
pKa values for identifying any correlation with efflux activity (Table.30). Pyrimidine, N-
methyl imidazole and thiazole were substituted for pyridine as the C-ring. The pKa value 
was calculated using Chemaxon software, while the logP and totat polar surface area 
(TPSA) were calculated using Molinspiration software. The cellular assay were carried 
out on E.coli. The control strain used is the ATCC Ec 25922, while JWO451 is an acrB 
efflux pump knock out strain, and BW25113 is the control stain for JW0451. Fold change 
was calculated from the ratio of BW25113 to JW0451. The pyrimidine substitution had 
the lowest pKa and lacked potency in both the control stains. Imidazole with a pKa of 2.7 
had better activity in both the control strains relative to pyrimidine, but the efflux ratio 
was similar to pyrimidine. The thiazole moiety had the most potent activity in the series 
close to pyridine, but the efflux ratio was twice that of UCP1038. Efflux is still the 
dominant mode of resistance for the dioxolane series. More substrates in the dioxolane 
series are required to cull out the relationship between efflux pump and the ligand 
properties. 
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Table 30. Changing the C-ring in the dioxolane series  
5.5 New pharmacophore 
 The propargyl linked antifolates were always built with B and C-rings coupled to 
the diaminopyrimidine through a propargylic linker. Though steady progress is being 
made to gain potency with the current pharmacophore, a new structural motif could 
provide the necessary breakthrough. The idea of using tropolones as the B-ring, while the 
diaminopyrimdine with the propargyl linker stays intact was conceived. The logic behind 
the use of tropolones is because of its metal chelating ability. The tropolone motif may 
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work by chelating the outer membrane ions Mg2+/Ca2+, and potentially gaining access to 
the periplasm. It could also potentiate the activity of the carbapenems by scavenging off 
the Zn2+ ions that are important for metallo-β lactamases to deactivate carbepenems. 
Finally with the diaminopyrimdine as the A-ring, it can anchor to the active site of 
DHFR, thereby acting as an antifolate. 
5.5.1. Synthesis of tropolone antifolate 
 Tropolone was converted to methoxy under standard conitions (Scheme.23), 
followed by bromination with NBS. The next step was to synthesize the alkynol so that 
the methylation/ deoxygenation strategy can be utilized. Unfortunately, with Grignard 
and n-butyl-lithium reagents, ring contracted phenyl substituted products are obtained. 
 
Scheme 23. Synthesis of bromo tropolones 
 
 So the coupling chemistry (Scheme.24) was utilized to overcome the limitations 
of metal exchange reactions. Stille coupling with vinyl ester stannane was carried out, 
followed by hydrogenation of the allyl ester. 
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Scheme 24. Synthesis of homologated ester of tropolones 
 Further reactions of reduction, Ohira Bestmann homologation and Sonogshira 
coupling with diamino iodopyrimdine are to be carried out in the future. 
5.6 Conclusions 
 Compounds that are active against the test strain for Klebsiella were designed and 
synthesized. Dioxolane series of compounds exhibit good potency against Escherichia 
coli strains. The benzodioxole moieties are less susceptible to efflux compared to the 
other pharmacophore. Efforts are directed towards reducing the efflux activity in 
dioxolane compounds and also new pharmacophores are being synthesized to gain 
activity with the gram negative pathogens. 
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CHAPTER 6 
Tandem metathesis to synthesize the Spirocyclic core of Cylopamine 
 
Introduction 
Cyclopamine is a steroidal alkaloid extracted from corn lily (Veratrum 
californicum). When pregnant ewes grazed upon these corn lily, the offspring developed 
a condition1-3 called cyclopia. Cyclopia is characterized by lack of differentiation of the 
brain frontal lobes into left and right hemishperes resulting in a fused nasal chamber with 
the eye in the middle. The other teratogenic alkaloids (Fig.24) include jervine and 
glucosylcyclopamine (cycloposine).  
 
Figure 24. Teratogenic alkaloids 
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Beechey et al identified the seven transmembered receptor - Smoothened (Smo) 
of the Hedgehog (Hh) signaling pathway as the target4 for cyclopamine. They also found 
that the binding of cyclopamine5 to Smo effectively reverses the oncogenic mutations by 
balancing the active and inactive form of smoothened receptor. 
6.1 Hedgehog Signaling Pathway 
 
 
The components of the Hh signaling pathway consists6 of Hh ligands (Fig.25) 
[Sonic Hh (SHh), Indian Hh(IHh) and Desert HH(DHh)], 12 transmembered patched 
(Ptch) receptor7, transmembered Smoothened (Smo) receptor and glioma (Gli) associated 
oncogene family of zinc-finger transcription factors. The Hh signaling is activated by the 
Figure 25. Hedgehog signaling pathway a. In the absence of Hedgehog ligand, b. In the 
presence of Hedgehog ligand 
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binding of the Hh ligands onto the Ptch membrane. The binding relieves the inhibition of 
Smo by Ptch, which translocate to the cell surface activated by an endogenous ligand. 
The translocation of Smo leads to downstream activation of GliA which in turn stimulates 
the production of Hh target genes in the nucleus. This cascade signaling pathway is 
usually active during embryogenesis for tissue growth and differentiation. In adults, the 
pathway is activated by tissue damage stimulating tissue repair, otherwise it remains 
dormant. The dormant state of the pathway is characterized by the absence of Hh ligand 
to activate the Ptch membrane. Inactivation of Ptch leads to internalization of Smo caused 
by the inhibition of Ptch. This leads to repressor form of Gli-GR being active and hence 
the Hh gene activation is stalled.  
6.2 Hedgehog signaling in cancer 
 The aberrant signaling of Hh pathway has been implicated in several forms of 
cancer7, most notably in basal cell carcinoma (BCC) and medulloblastoma. In the case of 
BCC, mutations in Ptch and Smo genes lead to cell proliferation. Mutation in Ptch 
relieves the suppression of Smo and alteration with Smo genes leads to decreased 
susceptibility towards Ptch. 
 Medullablastoma affecting the cerebellum of young adults is due to the mutation 
in Ptch gene accounting for 10% of the population while a majority of the mutation 
occurs in the REN gene responsible for neuroblast differentiation during embryonic 
stages.  Apart from the above two malignancy, irregular Hh signaling is also responsible 
for Small Cell Lung Carcinoma (SCLC), colon, pancreatic and prostate cancer. 
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6.3 Synthesis of Cyclopamine and its derivatives 
 Even though the cyclopamine inhibits the Smo with an EC50 of 300 nm, the 
clinical use of the steroidal alkaloid has been hampered by its low availability. Keeler’s 
extraction9 from the roots of veratrum californicum yielded 320mg of cyclopamine per kg 
of dried roots. Cooper et al achieved an overall yield10 of 0.13% by Soxhlet extraction 
from corn lily and recrystallization. Apart from the small molecule antognists8 developed 
for Hh pathway, total synthesis of cyclopamine have always captured the imagination of 
organic chemists. Keeler synthesized cyclopamine from jervine9 by Wolf Kishner 
reduction, while a formal synthesis was carried out by Masamune11 to build jervine and 
eventually using Keeler’s protocol to get the cyclopamine. A semisynthetic total 
synthesis12 was carried out by Giannis et al who achieved an overall yield of 1% over 20 
steps.  
Other limitations of cyclopamine are its low solubility – 5 µg/mL at pH, cytotoxic 
at concentrations greater than 10µM coupled with its instability in acidic medium 
(Scheme.25). At low pH, the tetrahydrofuran E ring opens up followed by aromatization 
of the D ring to form veratramine. Veratramine does not exhibit any antiproliferative 
activity against Smo.  
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Scheme 25. Acid labile cyclopamine 
 
 To overcome the above constraints, several modifications to cyclopamine have 
been carried out. Taipale et al 5 synthesized 3-keto, N-aminoethyl aminocaproyl 
dihydrocinnamoyl cycloamine (KAAD – cyclopamine) which became more potent 
exhibiting an IC50 of 20 nm. Srinivas et al synthesized a targeted delivery of cyclopamine 
prodrug against prostate cancer, by functionalizing the amine of the alkaloid with a 
peptide specific to prostate13 specific antigen. Similar functionalization of the secondary 
amine was carried out with carbohydrates14 that had improved potency against lung 
cancer cell line.  
In an effort to overcome the acid liability, researchers at Infinity 
pharmaceuticals15 (Fig.26) developed an expanded seven membered D ring through a 
chemoselective cycloproponation and acid catalyzed rearrangement. This strategy 
reduces the hydrolysis of tetrahydrofuran ring mediated by allylic ether reactivity. With 
improved stability of the E-ring, they modified the A-ring to exhibit better 
pharmacokinetic properties16 resulting in the synthesis of IPI-926. Another method to 
 
 
124 
 
improve the stability of cyclopamine at low pH was carried out by Giannis17 et al who 
installed an exocyclic methylene group on the D-ring.  
Efforts to improve the metabolic stability was also accomplished by Winkler et al 
who designed an estrone18 based simplified analog of cyclopamine having potency 
similar to the natural product at 10 µM. SAR studies19 were carried out on the estrone 
analog which was further refined from the aromatic pyridine to the saturated piperidine 20 
analog. 
 
Figure 26. Analogs of cyclopamine 
 Encouraged by the potent inhibitory activity of the cyclopamine analogs, an 
attempt has been made to explore the synthesis of DEF-ring fragment of the alkaloid in 
the shortest possible route. 
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6.4 Retrosynthesis of Cylopamine 
Cycloapamine can be assembled by convergent synthesis from the union of 
fragments 1 and 2 and eventual formation of cyclopentyl C-ring (Scheme.26). It was 
envisioned that the DEF-rings of fragment 2 can be built from a highly substituted 
oxabicyclic core through a tandem ring opening/closing metathesis reaction. The 
bicycloheptadiene moiety 3 can be obtained by Diels alder reaction between substituted 
furan 4 and an appropriate dienophile. 
 
Scheme 26. Retrosynthesis of cyclopamine 
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6.5 Synthesis of DEF fragment 
 The starting precursor 5 was obtained by the lithiation of furan and quenching the 
reaction with 1-bromopentene to give 2-pentenyl furan. When the substituted furan was 
treated thermally with methylpropiolate, no Diels Alder product was obtained.  But in the 
presence of Lewis acids21 Me2AlCl or MeAlCl2, phenolic product 7 was obtained from 
the in-situ cleavage of bridged Diels Alder adduct 6. In order to increase the reactivity of 
Diels Alder reaction, a deactivated dienophile was required. Bromopropiolate was 
obtained by the NBS mediated bromination of methylpropiolate22, catalyzed by AgNO3. 
Subsequently, Diels Alder reaction between bromopropiolate (Scheme.27) and 2-
methylfuran gave a highly selective oxabicyclo[2.2.1]heptadiene 8a in high yields with 
negligible amount of the undesired regioisomer 8b. 
 
Scheme 27. Diels Alder reaction with 2-pentenyl furan 
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The oxabicyclo adduct 8a was subjected to substitution with amine nucleophiles 
to install the C-22 side chain. A double substitution of the amine was observed, possibly 
to relieve the strain of the two sp2 centers of bromoenoate bicyclic adduct. To overcome 
the redundant double addition, reduction of β-bromide was investigated. The cyclic 
adduct 8b was subjected to zinc-silver couple23,24 reduction reaction in a buffered solution 
(Scheme.28). This generated the Michael acceptor 6 which was very unstable.  
Fortunately a one pot reaction was devised to carry out the Zn-Ag couple 
mediated dehalogenation followed by allylamine addition in situ to give the adduct 9 as a 
single diastereomer. It was found by NOE that the addition of allylamine had occurred 
exclusively from the exo position setting up the correct relative stereochemical 
relationships between C-23 and C-17/22. The protonation after the conjugate addition 
also occurred syn to the allylamine inverting the stereocenter at C-20. The substituted 
adduct 9 was protected with Boc anhydride to give the precursor 10. 
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Scheme 28. One pot synthesis functionalization of oxabicyclic adduct 
 The precursor 10 was subjected to a cascade ring opening/closing metathesis 
(Scheme.29) reaction with second generation Grubbs catalyst. Quite excitedly, the 
reaction underwent metathesis mediated bond reorganization rapidly at room temperature 
to give the tricyclic DEF spiroannulated ring in excellent yield.  
 
Scheme 29. Tandem metathesis to the spirocyclic core of cyclopamine 
Based on the success of the metathesis reaction with 2-pentenyl furan, efforts 
were directed towards synthesizing the analog of IPI-926 using 2-hexenyl furan 12. 
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Tandem metathesis reaction was carried out for 13 which gave seven membered tricyclic 
analog 14 in good yields (Scheme.30). 
 
Scheme 30. Seven membered analog of cyclopamine 
 Although spirocyclic analogs were obtained in good yields for both the 6 and 7-
membered ring system, the relative stereochemistry at C-20 is opposite to that of the 
natural product. In order to correct for the inversion at C-20 a new synthetic methodology 
was developed. 
6.6 Inversion of methyl substitution at C-20 
 It was realized that the best way to set the methyl group at C-20 is by enolate 
based alkylation reaction. This methodology will utilize the geometry of the molecule for 
the electrophile to add from the exo face. 
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6.6.1 Retrosynthesis  
 While the tandem metathesis reaction forms the linchpin for accessing the 
spirocyclic tricycle, the intermediate 15 is envisioned to set the stereochemistry at C-21 
and C-22. Alkylation of 15 with iodomethane followed by reduction of the ketone and 
Mitsunobu reaction with sodium azide was hypothesized to engender 3 with the right 
stereochemistry (Scheme.31). 
 
 
Scheme 31. Retrosynthesis 11 for the spirocyclic core of cyclopamine 
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6.6.2 Synthesis of Oxabicyclohepatadiene 15 
To synthesize the bicyclic adduct 15 through the Diels Alder reaction, a new 
dienophile has to be utilized.   
 
Scheme 32. Oxabicyclic adduct of β-keto allyl ester 
The allyl 3-bromoprop-2-ynoate25 underwent Diels Alder reaction with 2-pentenylfuran5 
to give the oxabicyclic compound 16a (Scheme.32).The double addition of amine 
nucleophile observed in the previous methodology was utilized to generate the aminal 
with dimethylamine. In situ hydrolysis of the aminal gave the β-keto ester 17. 
6.6.3 Decarboxylation 
 The β-keto ester was subjected to Tsuji decaboxylation26 catalyzed by Pd(PPh3)4 
in the presence of morpholine as the allyl scavenger. The equivalence of morpholine used 
was found to be a critical parameter for improving the yields. Initially, when 5 eq of the 
scavenger was used, no product formation was observed. Instead a nucleophilic 
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substitution of morpholine to the ketone was observed resulting in a ring cleavage 
product (Scheme.33).  
 
Scheme 33. Decarboxylation of β-keto allyl ester 
After a series of optimization, it was found out that initially 1 eq of morpholine 
should be added to the mixture of β-keto ester and palladium in ether. Once the allyl 
group has been completely scavenged by the morpholine, as observed by the 
disappearance of starting material on the TLC, another 1eq of morpholine is added to trap 
the acid as the carboxylate salt. The precipitating solids were filtered, dissolved in 
dichloromethane and refluxed for 8h to get the decarboxylated ketone 19. 
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6.6.4 Methylation 
 The oxabicyclo heptenenone 19 was subjected to alkylation with LiHMDS and 
iodomethane. Low yields of the product were obtained along with starting material and 
concomitant formation of aldol product as observed in the literature27. A screening of the 
bases – NaHMDS, KHMDS, NaH, K-OtBu provided better yields with KHMDS, but the 
formation of aldol product could not be eliminated.  
 
Scheme 34. Methylation of oxabicycloheptenone 
With KHMDS as the base (Scheme.34), reaction conditions were optimized to 
overcome the self-condensation. Initially, when the temperature was lowered to -95 to -
90oC, a greater proportion of the starting material with little to no product formation. 
When KHMDS was added to a precooled mixture of ketone and iodomethane in THF at -
78oC, aldol product was still observed. Similar results were seen when ketone was added 
to a mixture of KHMDS and iodomethane. Alternatively, when ketone was added 
dropwise for 24 hrs at -60oC to the base and electrophile, starting material was recovered. 
It was decided to postpone further optimization until the viability of the substitution 
reaction with azide has been tested in the next step. 
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6.6.5. Nucleophilic substitution reaction 
 The methylated ketone 20 was reduced with NaBH4 to obtain the endo alcohol 22 
in 95% yield. When the alcohol was subjected to Mitsunobu conditions with 
diphenylphosphoryl azide a trace of azide formation (Scheme.35) was observed along 
with a cluster of non –separable side products. Nucleophilic substitution of tosylated 22 
with sodium azide in DMF generated the starting material. Treatment of endo alcohol 22 
with DPPA (Ref) and DBU generated the alkoxyphosphonium species that did not 
undergo displacement with the azide. The alkoxyphosphonium species was separated by 
column and subjected to displacement with sodium azide in DMF. No reaction was 
observed even after heating the reaction mixture to 92oC.  
 
Scheme 35. SN2 reaction with azide 
Finally the leaving group was changed to a triflate and subjected to azide in DMF. 
A trace of product was observed along with several side products. 
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6.6.6 Reductive amination 
 Since the nucleophilic substitution did not provide the azide in reasonable yields, 
an alternate strategy was devised. The reductive amination was proposed as an alternate 
to azide substitution since it precludes the additional step of Staudinger reaction to 
convert the azide to an amine. The main limitation of the reductive amination is in setting 
up the relative stereocenter at C-23. In this case, the hydride will be delivered from the 
exo face, forcing the amine endo to the methyl group at C-20. But it could be overcome 
by utilizing a bulky reducing agent thereby forcing the hydride transfer from the endo 
face of the molecule.  
 The one pot reductive amination generated several products along with the 
reduced alcohol. Hence the reaction was carried out sequentially by the formation of 
imine followed by reduction with sodium triacetoxyborohydride(Scheme.36).  
 
Scheme 36. Reductive amination of oxabicycloheptenone 
 The use of bulky NaBH(OAc)3 generated the endo isomer more than the required 
exo isomer. Bulkier reducing agents were synthesized by treating NaBH4 with 
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ethylhexanoic acid, isobutyric acid, butyric acid. But no reaction was observed with these 
reagents. Further optimization of reductive amination is required to enhance the 
stereoselective reduction of the imine.  
It is anticipated that the remaining steps of boc protection followed by metathesis 
reaction will engender the tricyclic DEF system efficiently.  
6.7 Conclusion 
 A simplified analog of the cyclopamine was synthesized from the highly 
substituted oxabicyclic adduct using the tandem ring opening/closing metathesis reaction. 
The relative stereochemistry at C-20 was opposite to the natural product. Efforts to set 
the right stereocenter was achieved by a new methodology. But a series of bulky reducing 
agents have to be screened to favor the exo amine synthesis at C-23. 
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CHAPTER 7 
Experimental Procedures 
 
The 1H and 13C NMR spectra were recorded on Bruker instruments at 500 MHz. 
Chemical shifts are reported in ppm and are referenced to residual CHCl3 solvent; 7.24 
and 77.23 ppm for 1H and 13C, residual solvent MeOH; 4.78, 3.31 and 49.15 ppm 
respectively. Melting points were recorded on Mel-Temp 3.0 apparatus and are 
uncorrected. The high-resolution mass spectrometry was provided by the Notre Dame 
Mass Spectrometry Laboratory and University of Connecticut Mass Spectrometry 
Laboratory using AccuTOF mass spectrometer and/or using DART source. IR data were 
obtained using Alpha diamond ATR probe. TLC analyses were performed on Sorbent 
Technologies silica gel HL TLC plates. All glassware was oven-dried and allowed to cool 
under an argon atmosphere. Anhydrous dichloromethane, ether, and tetrahydrofuran were 
used directly from Baker Cycle-Tainers. Anhydrous Dimethylformamide was purchased 
from Acros and degassed by purging with argon. Anhydrous triethylamine was purchased 
from Aldrich and degassed by purging with argon. All reagents were used directly from 
commercial sources unless otherwise stated. Boronic acids for Suzuki coupling were 
purchased from Frontier Scientific, Inc.  
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General procedure for the Suzuki Coupling  
An oven dried 100mL pressure vessel with stir bar was cooled to room temperature under 
argon. Bromo aldehyde, boronic acid and Cs2CO3 in mL anhydrous dioxane were stirred 
and purged under argon for 15 minutes. Pd(PPh3)2Cl2 was then added and purging 
continued for further 10 minutes. The pressure vessel was sealed with a screw cap and 
placed in a preheated oil bath at 80 oC for 12 h. The dark colored reaction mixture was 
cooled, diluted with ether, filtered through celite and rinsed with ether. The filtered 
solution was concentrated, diluted with CH2Cl2, pre-absorbed onto silica gel and purified 
by column chromatography.  
 
 
 
 
According to the general Suzuki coupling procedure Bromo aldehyde (3.50 g, 16.5 
mmol), pyridine-4-boronic acid (4.05g, 32.94 mmol), Cs2CO3 (16.09 g, 4.93 mmol), 
Pd(PPh3)2Cl2 ( 1.16 g, 1.65 mmol, 10% Pd) and anhydrous dioxane (16.5  mL) was 
heated at 80 oC for 12h (overnight). Following the general workup and flash 
chromatography (SiO2, 60 g, 50% EtOAc/hexanes) biaryl aldehyde was obtained as a pale 
white solid (3.9 g, 85%): TLC Rf = 0.13 ( 50% EtOAc/hexanes); 1H NMR (500 MHz, 
CDCl3) δ 10.47 (s, 1H), 8.60 (d, J = 5.0 Hz, 2H), 8.09 (d, J = 5.0 Hz, 1H), 7.81 (dd, J = 
N
O O
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15.0, 5.0 Hz, 1H), 7.44 (d, J = 10.0 Hz, 2H), 7.07 (d, J = 10.0 Hz, 1H), 3.95 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 189.2, 162.3, 150.3, 146.5, 133.9, 130.4, 126.8, 125.1, 120.9, 
112.5, 55.9; IR (neat cm-1) 3063, 2976, 2896, 1677,1603, 1271, 804, 504; HRMS 
(DART, M+ + H) m/z 214.0886 (calculated for C13H11NO2, 214.0868). 
 
N N
O O
 
 
According to the general Suzuki coupling procedure Bromo aldehyde (1.50 g, 6.97 
mmol), pyrimidine-5-boronic acid (1.73 g, 13.95 mmol), Cs2CO3 (6.81 g, 20.91 mmol), 
Pd(PPh3)2Cl2 ( 0.49 g, 0.70 mmol, 10% Pd) and anhydrous dioxane (5 mL) was heated at 
80 oC for 12h (overnight). Following the general workup and flash chromatography 
(SiO2, 30 g, 50% EtOAc/hexanes) biaryl aldehyde was obtained as a pale white solid 
(1.04 g, 70%): TLC Rf = 0.2 ( 50% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 10.51 
(s, 1H), 9.18  (s, 1H), 8.93 (s, 2H), 8.06 (d, J = 2.0 Hz, 1H), 7.77 (dd, J = 8.5, 2.5 Hz, 
1H), 7.15 (d, J = 9.0 Hz, 1H), 3.99(s, 3H); 13C NMR (125 MHz, CDCl3) δ 189.3, 162.5, 
157.7, 154.7, 134.2, 133.2, 127.1, 127.0, 125.6, 113.1, 56.24; IR (neat cm-1) 3035, 2849, 
2760, 1742, 1606, 1498, 1414, 1387, 1186, 1014, 722; HRMS (DART, M+ + H) m/z 
215.0841 (calculated for C12H10N2O2, 215.0821). 
 
 
144 
 
N
N
O O
 
 
 
According to the general Suzuki coupling procedure Iodopyrazine (1.11 g, 5.39 mmol), 
3-formyl-4-methoxyphenylboronic acid (1.94g, 10.78 mmol), Cs2CO3 (5.27 g, 16.17 
mmol), Pd(PPh3)2Cl2 ( 0.4 g, 0.54 mmol, 10% Pd) and anhydrous dioxane (6  mL) was 
heated at 80 oC for 12h (overnight). Following the general workup and flash 
chromatography (SiO2, 30 g, 50% EtOAc/hexanes) biaryl aldehyde was obtained as a pale 
white solid (0.84 g, 73%): TLC Rf = 0.3 ( 50% EtOAc/hexanes); 1H NMR (500 MHz, 
CDCl3) δ 10.49 (s, 1H), 9.01  (s, 1H), 8.57 (s, 1H), 8.45 (dd, J = 9.5, 2.0 Hz, 2H), 8.29 
(dd J = 8.5, 2.0 Hz, 1H) 7.12 (d, J = 8.5 Hz, 1H), 3.98 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 189.4, 163.1, 151.5, 144.3, 143.0, 141.8, 134.5, 129.2, 127.1, 125.2, 112.7, 
56.2; IR (neat cm-1) 3055, 2980, 2884, 1675, 1604, 1454, 1414, 1392, 1272, 1256, 1112, 
1010, 825, 512; HRMS (DART, M+ + H) m/z 215.0831 (calculated for C12H10N2O2, 
215.0821). 
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N
O
O
 
According to the general Suzuki coupling procedure Bromo aldehyde (1.7 g, 7.91 mmol), 
pyridine-4-boronic acid (1.94g, 15.81 mmol), Cs2CO3 (7.72g, 23.72 mmol), Pd(PPh3)2Cl2 
( 0.55g, 23.72 mmol, 10% Pd) and anhydrous dioxane (8  mL) was heated at 80 oC for 
12h (overnight). Following the general workup and flash chromatography (SiO2, 20 g, 
50% EtOAc/hexanes) biaryl aldehyde was obtained as a pale white solid (1.38 g, 82%): 
TLC Rf = 0.2 ( 50% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 10.00 (s, 1H), 8.66  
(d, J = 6.0 Hz, 2H), 7.67 (s, 1H), 7.48 (d, J = 9.5 Hz, 2H), 7.37 (d, J = 1.5 Hz, 1H), 3.89 
(s, 3H); 13C NMR (125 MHz, CDCl3) δ 191.7, 160.9, 150.7, 146.9, 140.7, 138.7, 121.8, 
119.9, 112.9, 100.1, 55.9; IR (neat cm-1) 3013, 2972, 2834, 1693, 1586, 1468, 1217, 
1151, 1046, 852,  816; HRMS (DART, M+ + H) m/z 214.0897 (calculated for C13H11NO2, 
214.0868). 
N
O
O
O
 
According to the general Suzuki coupling procedure Bromo aldehyde (1.06 g, 4.33 
mmol), pyridine-4-boronic acid (1.06 g, 8.65 mmol), Cs2CO3 (4.22 g, 12.98 mmol), 
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Pd(PPh3)2Cl2 ( 0.3 g, 0.43 mmol, 10% Pd) and anhydrous dioxane (4.3  mL) was heated 
at 80 oC for 12h (overnight). Following the general workup and flash chromatography 
(SiO2, 30 g, 50% EtOAc/hexanes) biaryl aldehyde was obtained as a pale yellow solid 
(0.84 g, 80%): TLC Rf = 0.2 ( 50% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 9.92 
(s, 1H), 8.66  (d, J = 5.5 Hz, 2H), 7.49 (d, J = 2.0 Hz, 1H), 7.45 – 7.44 (comp, 3H), 3.96 
(s, 3H), 3.73 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 190.1, 154.0, 152.2, 150.1, 145.1, 
133.5, 132.8, 126.4, 124.1, 111.2, 61.3, 56.4; IR (neat cm-1) 3058, 3016, 2838, 2708, 
1692, 1579, 1460, 1297, 1048, 816; HRMS (DART, M+ + H) m/z 244.0999 (calculated 
for C14H13NO3, 244.0974). 
N
O
O
O
 
According to the general Suzuki coupling procedure Bromo aldehyde (3.04 g, 13.28 
mmol), pyridine-4-boronic acid (3.26 g, 26.56 mmol), K3PO4 (4.8 g, 22.58 mmol), 
Pd2(dba)3 ( 1.21 g, 1.32 mmol, 10% Pd), P(Cy)3 (1.11 g, 3.9 mmol) and anhydrous 
dioxane (35.9 mL), H2O (17 mL) was heated at 100 oC for 12h (overnight). Following the 
general workup and flash chromatography (SiO2, 60 g, 50% EtOAc/hexanes) biaryl 
ketone 10 was obtained as a pale white solid (2.41 g, 80%): TLC Rf = 0.2 ( 50% 
EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 9.87 (s, 1H), 8.69  (d, J = 6 Hz, 2H), 
7.67 – 7.64 (comp, 3H), 7.36 (d, J = 1.5 Hz, 1H), 6.18 (s, 2H); 13C NMR (125 MHz, 
CDCl3) δ 190.1, 150.8, 150.6, 149.7, 142.0, 132.5, 127.0, 122.2, 120.0, 107.5, 102.8; IR 
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(neat cm-1) 3337, 3062, 2915, 1685, 1594, 1402, 1097, 891; HRMS (DART, M+ + H) m/z 
228.0689 (calculated for C13H9NO3, 228.0661). 
 
Bromo aldehyde (0.8 g, 3.49 mmol), pyrimidine-5-boronic acid (0.86 g, 6.99 mmol), 
K3PO4 (1.26 g, 5.94 mmol), Pd2(dba)3 ( 0.32 g, 0.35 mmol, 10% Pd), P(Cy)3 (0.29 g, 1.05 
mmol) anhydrous dioxane (9.4 mL), H2O (4.7 mL) was heated at 100 oC for 12h 
(overnight). Following the general workup and flash chromatography (SiO2, 20 g, 50% 
EtOAc/hexanes) biaryl aldehdye was obtained as a pale white solid (0.58 g, 73%): TLC 
Rf = 0.3 ( 50% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 9.89 (s, 1H), 9.21 (s, 1H), 
9.10 (s, 2H), 7.62  (d, J = 1.5 Hz, 1H), 7.39 (d, J = 1.5 Hz, 1H), 6.19 (s, 2H); 13C NMR 
(125 MHz, CDCl3) δ 189.8, 158.2, 155.6, 150.6, 149.7, 132.9, 128.8, 126.3, 116.2, 107.9, 
102.9; IR (neat cm-1) 3062, 2919, 2795, 1682, 1411, 1253, 1091, 933, 720; HRMS 
(DART, M+ + H) m/z 229.0628 (calculated for C12H8N2O3, 229.0613). 
O
N
N
O
 
According to the general Suzuki coupling procedure 5-bromo-1-methyl-1H-imidazole 
(1.05 g, 6.5 mmol), 3-formyl-4-methoxyphenyl boronic acid (1.75 g, 9.75 mmol), sat. 
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Na2CO3 (3.25 mL), PdCl2dppf (0.095 g, 0.13 mmol, 2 mol% Pd) and anhydrous ethanol 
(30  mL), toluene (5 mL) was heated at 85 oC for 2h. Following the general workup and 
flash chromatography (SiO2, 20 g, 3%MeOH/CH2Cl2) biaryl aldehyde was obtained as a 
orange solid (0.98 g, 70%): TLC Rf = 0.06 ( 3%MeOH/CH2Cl2); 1H NMR (500 MHz, 
CDCl3) δ 10.5 (s, 1H), 7.81 (d, J = 2.0 Hz, 1H), 7.56 (dd, J = 6.0, 2.0 Hz, 1H), 7.51  (b, 
1H), 7.05 (d, J = 9.0 Hz, 2H), 3.96 (s, 3H), 3.62 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
189.8, 158.2, 155.6, 150.6, 149.7, 132.9, 128.8, 126.3, 116.2, 107.9, 102.9; IR (neat cm-1) 
3101, 2971, 2945, 2860, 2768, 1681, 1614, 1482, 1245, 1114, 1017, 827; HRMS (DART, 
M+ + H) m/z 217.0998 (calculated for C12H12N2O2, 217.0977). 
 
According to the general Suzuki coupling procedure 4-iodo-3,5-dimethylisoxazole (1.14 
g, 5.1 mmol), 3-formyl-4-methoxyphenyl boronic acid (4.5 g, 25.5 mmol), Na2CO3 (3.5 
g, 33.15 mmol), Pd(PPh3)4 ( 0.115 g, 0.10 mmol, 2% Pd), anhydrous dioxane (75 mL), 
H2O (17 mL) was heated at 85 oC for 2h. Following the general workup and flash 
chromatography (SiO2, 30 g, 50% EtOAc/hexanes) biaryl aldehyde was obtained as a pale 
white solid (1.04 g, 88%): TLC Rf = 0.6 ( 50% EtOAc/hexanes); 1H NMR (500 MHz, 
CDCl3) δ 10.5 (s, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.41 (dd, J = 8.5, 2.5 Hz, 1H), 7.05 (d, J 
= 8.5 Hz, 1H), 3.95 (s, 3H), 2.35 (s, 3H), 2.21 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
189.5, 165.5, 161.3, 158.7, 137.0, 129.0, 125.2, 123.2, 115.5, 112.5, 56.1, 11.7, 10.9; IR 
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(neat cm-1) 3038, 2923, 2862, 2724, 1682, 1601, 1268, 1120, 1014, 825; HRMS (DART, 
M+ + H) m/z 232.0993 (calculated for C13H13NO3, 232.0976). 
 
 
According to the general Suzuki coupling procedure Bromo aldehyde (0.56 g, 2.93 
mmol), pyridine-4-boronic acid (0.72 g, 5.86 mmol), Cs2CO3 (2.86 g, 8.79 mmol), 
Pd(PPh3)2Cl2 ( 0.21 g, 0.3 mmol, 10% Pd) and anhydrous dioxane (5  mL) was heated at 
80 oC for 12h (overnight). Following the general workup and flash chromatography 
(SiO2, 20 g, 50% EtOAc/hexanes) biaryl aldehyde was obtained as a pale white solid 
(0.44 g, 80%): TLC Rf = 0.2 ( 50% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 9.91 
(s, 1H), 8.66 (d, J = 4.5 Hz, 2H), 7.76 (d, J = 4.0, 1H), 7.55 (d, J = 3.5 Hz, 1H), 7.50 (d, J 
= 5.0 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 182.9, 151.0, 150.3, 144.4, 140.2, 137.1, 
126.2, 120.4; IR (neat cm-1) 3304, 3091, 1713, 1415, 1214, 1047, 799; HRMS (DART, 
M+ + H) m/z 190.0351 (calculated for C10H7NOS, 190.0327). 
Alkynol Synthesis 
A 50 mL flask with stir bar was flame dried under argon. THF (0.1M) was added and 
temperature lowered to 0 oC.  Ethynyltrimethyl silane was added and reaction mixture 
stirred for 2 minutes. Isopropyl magnesium chloride was added dropwise and stirred 
initially at 0 oC for 30 minutes followed by another 30 minutes at room temperature. The 
grey colored Grignard reagent was cooled to 0 oC and the aldehyde in THF was added 
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dropwise for 5 minutes. The reaction was followed by TLC quenched with water and sat. 
NH4Cl. The organic layer was separated and water layer extracted 3 times with ether. The 
combined organic extracts were dried with MgSO4 filtered and rotoevaporated. The 
crude compound was preabsorbed onto silica gel and purified by column 
chromatography. 
N
OOH
Si
 
According to the general nucleophilic addition Ethynyltrimethyl silane (6.6mmol, 
0.93mL) in THF (2M, 3.29mL) and isopropyl magnesium chloride (2M, 3.3mL) was 
stirred. At 0 oC was added the aldehyde (5.06mmol, 1.07g) in THF (0.1M, 
50.6mL).Following the general workup and flash chromatography (SiO2, 40 g, 
3%MeOH/CH2Cl2) alkynol 10 was obtained as a white solid (1.48 g, 94%): TLC Rf = 0.1 
(3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.58 (d, J = 5.7 Hz, 2H), 7.91 (d, J = 
2.2 Hz, 1H), 7.58 (dd, J = 8.5, 2.2  Hz, 1H), 7.44 (d, J = 6.0 Hz, 2H), 6.98 (d, J = 8.5 Hz, 
1H), 5.77 (s, 1H), 3.92 (s, 3H), 0.19 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 158.0, 150.3, 
148.0, 130.5, 129.8, 128.3, 127.0, 121.2, 111.6, 104.7, 91.5, 61.0, 56.0, 0.1.; IR (neat cm-
1) 3139, 2977, 2868, 2165, 1562, 1504, 1228, 1011; HRMS (DART, M+ + H) m/z 
312.1393 (calculated for C18H21NO2Si, 312.1420). 
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According to the general nucleophilic addition Ethynyltrimethyl silane (3.55mmol, 
0.50mL) in THF (2M, 1.78mL) and isopropyl magnesium chloride (2M, 3.55mmol, 
1.78mL) was stirred. At 0 oC was added the aldehyde (2.37mmol, 0.51g) in THF (0.1M, 
23.6mL).Following the general workup and flash chromatography (SiO2, 20 g, 
3%MeOH/CH2Cl2) alkynol 10 was obtained as a white solid (0.7 g, 95%): TLC Rf = 0.1 
(3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 9.14 (s, 1H), 8.90 (s, 2H), 7.85 (s, 
1H), 7.52 (d, J = 10.7 Hz, 1H), 7.03 (d, J = 8.5 Hz, 1H), 5.77 (s, 1H), 3.93 (s, 3H), 0.18 
(s, 9H); 13C NMR (125 MHz, CDCl3) δ 157.9, 157.2, 154.6, 134.0, 130.1, 128.4, 126.9, 
126.9, 112.0, 104.2, 91.9, 61.1, 56.1, 0.1; IR (neat cm-1) 3177, 3010, 2837, 2164, 1608, 
1308, 1059; HRMS (DART, M+ + H) m/z 313.1391 (calculated for C17H20N2O2Si, 
312.1372). 
N
N
OOH
Si
 
According to the general nucleophilic addition Ethynyltrimethyl silane (1.45mmol, 
0.2mL) in THF (2M, 0.72mL) and isopropyl magnesium chloride (2M, 0.72mL) was 
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stirred. At 0 oC was added the aldehyde (0.9mmol, 0.2g) in THF (0.1M, 
9.7mL).Following the general workup and flash chromatography (SiO2, 10 g, 
3%MeOH/CH2Cl2) alkynol 10 was obtained as a white solid (0.27 g, 95%): TLC Rf = 0.1 
(3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.96 (s, 1H), 8.57 (s, 1H), 8.43 (d, J 
= 2.4 Hz, 1H), 8.28 (d, J = 2.2 Hz, 1H), 8.01 (dd, J = 8.6, 2.3,  Hz, 1H), 7.01 (d, J = 8.6 
Hz, 1H), 5.75 (s, 1H), 3.94 (s, 3H), 0.20 (s, 9H13C NMR (125 MHz, CDCl3) δ 158.6, 
152.5, 144.3, 142.4, 141.7, 129.6, 129.1, 128.7, 127.0, 111.6, 104.5, 91.7, 61.5, 56.1, 0.1. 
IR (neat cm-1) 3055, 2980, 2884, 2847, 1913, 1675, 1604, 1414, 1272, 1166, 1112, 1010, 
825; HRMS (DART, M+ + H) m/z 313.1394 (calculated for C17H20N2O2Si, 312.1372). 
 
According to the general nucleophilic addition Ethynyltrimethyl silane (2.1mmol, 0.3mL) 
in THF (2M, 1.0mL) and isopropyl magnesium chloride (2M, 1.0mL) was stirred. At 0 
oC was added the aldehyde (1.7mmol, 0.4g) in THF (0.1M, 17.4mL).Following the 
general workup and flash chromatography (SiO2, 20 g, 3%MeOH/CH2Cl2) alkynol 10 
was obtained as a bronish oil (0.51 g, 94%): TLC Rf = 0.1 (3%MeOH/CH2Cl2); 1H NMR 
(500 MHz, CDCl3) δ 8.59 (s, 2H), 7.46 (d, J = 4.5 Hz, 2H), 7.38 (s, 1H), 7.19 (s, 1H), 
7.07 (s, 1H), 5.50 (s, 1H), 3.85 (s, 3H), 0.18 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 
160.5, 150.1, 148.5, 143.5, 139.7, 122.0, 118.0, 113.1, 112.7, 105.4, 91.7, 64.7, 55.7, 0.0; 
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IR (neat cm-1) 3153, 2958, 2899, 2837, 2170, 1648, 1550, 1325, 1217, 1049; HRMS 
(DART, M+ + H) m/z 312.1434 (calculated for C18H21NO2Si, 312.1420). 
 
According to the general nucleophilic addition Ethynyltrimethyl silane (3.79mmol, 0.54 
mL,) in THF (2M, 1.9mL) and isopropyl magnesium chloride (2M, 1.9mL) was stirred. 
At 0 oC was added the aldehyde (2.5mmol, 0.6g) in THF (0.1M, 25.2mL).Following the 
general workup and flash chromatography (SiO2, 30 g, 50% 3%MeOH/CH2Cl2) alkynol 
10 was obtained as a colorless oil (0.82g, 95%): TLC Rf = 0.1 ( 3%MeOH/CH2Cl2); 1H 
NMR (500 MHz, CDCl3) δ 8.57 (d, J = 4.9 Hz, 2H), 7.45 (d, J = 6.0 Hz, 2H), 7.21 (d, J = 
1.75 Hz, 1H), 7.09 (d, J = 1.79 Hz, 1H), 5.45 (s, 1H), 3.91 (s, 3H), 3.59 (s, 3H), 0.18 (s, 
9H); 13C NMR (125 MHz, CDCl3) δ 153.4, 149.5, 146.7, 146.4, 137.3, 132.6, 124.3, 
120.4, 111.7, 105.5, 91.8, 64.6, 61.0, 56.2, 0.0;  IR (neat cm-1) 3085, 3009, 2964, 2821, 
2162, 1642, 1410, 1241, 1134, 1049, 828; HRMS (DART, M+ + H) m/z 342.1516 
(calculated for C19H23NO3Si, 342.1525). 
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According to the general nucleophilic addition Ethynyltrimethyl silane (3.78mmol, 
0.53mL) in THF (0.53mL) and isopropyl magnesium chloride (2M, 1.9mL) was stirred. 
At 0 oC was added the aldehyde (1.26mmol, 0.3g) in THF (0.1M, 12.6mL).Following the 
general workup and flash chromatography (SiO2, 15 g, 3%MeOH/CH2Cl2) alkynol 10 
was obtained as a yellow hygroscopic solid (0.41 g, 99%): TLC Rf = 0.1 
(3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.58 (d, J = 4.3 Hz, 2H), 7.61 (d, J = 
5.8 Hz, 2H), 7.28 (s, 1H), 7.09 (s, 1H), 6.05 (s, 2H), 5.42 (s, 1H), 0.18 (s, 9H); 13C NMR 
(125 MHz, CDCl3) δ 150.0, 148.8, 145.6, 143.6, 135.9, 122.3, 119.2, 119.0, 108.3, 105.4, 
101.8, 91.6, 64.5, 0.0; IR (neat cm-1) 3140, 2958, 2896, 2170, 1639, 1600, 1402, 1248, 
1195, 1044, 1002, 824; HRMS (DART, M+ + H) m/z 326.1223 (calculated for 
C18H19NO3Si, 326.1212). 
 
 
According to the general nucleophilic addition Ethynyltrimethyl silane (0.9mmol, 
0.14mL) in THF (2M, 0.5mL) and isopropyl magnesium chloride (2M, 0.99mmol, 0.5mL 
was stirred. At 0 oC was added the aldehyde (0.66mmol, 0.15g) in THF (0.1M, 
6.6mL).Following the general workup and flash chromatography (SiO2, 10 g, 
3%MeOH/CH2Cl2) alkynol 10 was obtained as a light yellow solid (0.21 g, 96%): TLC Rf 
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= 0.1 3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 9.14 (s, 1H), 9.05 (s, 2H), 7.24 
(s, 1H), 7.10 (s, 1H), 6.07 (s, 2H), 5.42 (s, 1H), 0.20 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 157.5, 155.5, 148.9, 145.5, 136.0, 129.8, 118.8, 115.3, 108.3, 104.8, 102.0, 
92.3, 64.7, 0.0; IR (neat cm-1) 3189, 2955, 2899, 2172, 1606, 1409, 1249, 1041, 1006, 
837; HRMS (DART, M+ + H) m/z 327.1190 (calculated for C17H18N2O3Si, 327.1165). 
 
According to the general nucleophilic addition Ethynyltrimethyl silane (2.0mmol, 
0.28mL) in THF (1.0mL) and isopropyl magnesium chloride (2M, 2.0mmol, 1.0mL) was 
stirred. At 0 oC was added the aldehyde (1.66mmol, 0.36g) in THF (0.1M, 
16.6mL).Following the general workup and flash chromatography (SiO2, 10 g, 
3%MeOH/CH2Cl2) alkynol 10 was obtained as a light yellow solid (0.49 g, 94%): TLC Rf 
= 0.03 (3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.62 (d, J = 2.1 Hz, 1H), 7.45 
(s, 1H), 7.27 (dd, J = 8.4, 2.2 Hz, 1H), 6.98 (s, 1H), 6.93 (d, J = 8.5 Hz, 1H), 5.76 (s, 1H), 
3.88 (s, 3H), 3.60 (s, 3H), 0.15 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 156.7, 138.8, 
133.2, 129.9, 129.6, 128.5, 127.5, 122.3, 111.3, 105.0, 90.9, 60.5, 55.9, 32.6, 0.1; IR 
(neat cm-1) 3113, 2957, 2899, 2837, 2167, 1488, 1279, 1040, 838; HRMS (DART, M+ + 
H) m/z 315.1532 (calculated for C17H22N2O2Si, 315.1529). 
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According to the general nucleophilic addition Ethynyltrimethyl silane (4.1mmol, 0.6mL) 
in THF (2M, 2.0mL) and isopropyl magnesium chloride (2M, 4.1mmol, 2.0mL) was 
stirred. At 0 oC was added the aldehyde (2.72mmol, 0.63g) in THF (0.1M, 27.2mL). 
Following the general workup and flash chromatography (SiO2, 20 g, 3%MeOH/CH2Cl2) 
alkynol 10 was obtained as a colorless oil (0.86 g, 96%): TLC Rf = 0.4 
(3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 7.17 (d, J = 8.1 Hz, 
1H), 6.95 (d, J = 8.1 Hz, 1H), 5.76 (d, J = 5.4 Hz, 1H), 3.90 (s, 3H), 2.38 (s, 3H), 2.24 (s, 
3H), 0.18 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 164.9, 158.7, 156.2, 130.2, 129.2, 
128.9, 122.7, 116.1, 111.3, 104.6, 91.0, 60.5, 55.8, 11.5, 10.8, -0.1; IR (neat cm-1) 3038, 
2923, 2862, 2724, 1682, 1601, 1245, 1176, 1120, 1014, 825; HRMS (DART, M+ + H) 
m/z 330.1528 (calculated for C18H23NO3Si, 330.1525). 
 
According to the general nucleophilic addition Ethynyltrimethyl silane (2.6mmol, 0.4mL) 
in THF (2M, 1.3mL) and isopropyl magnesium chloride (2M, 2.6mmol, 1.3mL) was 
stirred. At 0 oC was added the aldehyde (2.2mmol, 0.41g) in THF (0.1M, 
21.6mL).Following the general workup and flash chromatography (SiO2, 20 g, 
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3%MeOH/CH2Cl2) alkynol 10 was obtained as a brown solid (0.6 g, 95%): TLC Rf = 0.2 
(3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.49 (d, J = 6.2 Hz, 2H), 7.41 (d, J = 
6.2 Hz, 2H), 7.33 (d, J = 3.7 Hz, 1H), 7.14 (d, J = 4.4 Hz, 1H), 5.65 (s, 1H), 0.19 (s, 9H); 
13C NMR (125 MHz, CDCl3) δ 150.1, 147.7, 141.9, 141.1, 126.7, 125.3, 119.9, 104.4, 
91.3, 60.6, -0.1; IR (neat cm-1) 3181, 3017, 2112, 1592, 1494, 1414, 1219, 991.51, 
800.26; HRMS (DART, M+ + H) m/z 288.0901 (calculated for C15H17NOSSi, 288.0878). 
 
Methylation. 
To a 100 mL flame dried flask under argon was added CH2Cl2 (1M) at room temperature 
and cooled to 0 oC. TiCl4 (1M in toluene, 1 eq) was added followed by dimethyl zinc 
(1.2M in toluene, 2 eq) and stirred at 0 oC for 30 minutes. To the yellow heterogeneous 
mixture, alkynol (1eq) dissolved in 0.1 M CH2Cl2 was added dropwise for 10 mins. TLC 
was performed on a small aliquot quenched with MeOH. After ~1hr, the reaction was 
stopped by a slow dropwise addition of MeOH. Care should be taken to avoid frothing 
and addition of MeOH continued until the reaction turns into a homogeneous yellow 
solution. The crude mixture was stirred at room temperature for 5 minutes and pushed 
through a plug of silica gel. Solvent was rotoevaporated and deprotection of TMS alkyne 
dissolved in 0.2M EtOH was carried out by stirring initially for 30min with AgNO3 (3 eq) 
dissolved in 1.5M water. Then KCN (10 eq) dissolved in 10M H2O was added slowly and 
stirred for 1hr. The reaction mixture was diluted with EtOAc, washed with water and 
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dried with MgSO4. Solvent was rotoevaporated, the crude mixture was preabsorbed onto 
silica gel and column chromatography was carried out with 3% MeOH in CH2Cl2. 
 
 
N
O
 
 
According to the general methylation protocol, alkynol (0.33mmol, 0.10g) in CH2Cl2 was 
added to the pre-mixed solution of TiCl4 (0.33 mmol, 0.33mL) and dimethylzinc 
(0.66mmol, 0.5mL) in 1M CH2Cl2. Following the general workup and deprotection, the 
crude mixture was purified by flash chromatography (SiO2, 5g, 3% MeOH in CH2Cl2) 
methylated alkyne was obtained as a yellow solid (51.6mg, 66%): TLC Rf = 0.2 (3% 
MeOH in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.60 (d, J = 5.1 Hz, 2H), 7.87 (d, J = 
2.2 Hz, 1H), 7.63 – 7.32 (m, 3H), 6.93 (d, J = 8.5 Hz, 1H), 4.21 (qd, J = 7.0, 2.4 Hz, 1H), 
3.87 (s, 3H), 2.25 (d, J = 2.4 Hz, 1H), 1.46 (d, J = 7.04 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 157.2, 150.2, 148.2, 132.0, 130.5, 126.7, 126.6, 121.4, 111.1, 87.3, 70.2, 55.8, 
25.7, 22.9; IR (neat cm-1) 3222, 3075, 2980, 2108, 1594, 1484, 1255, 803; HRMS 
(DART, M+ + H) m/z 238.1256 (calculated for C16H15NO, 238.1232). 
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According to the general methylation protocol, alkynol (0.97mmol, 0.31g) in 0.1M 
CH2Cl2 was added to the pre-mixed solution of TiCl4 (0.97mmol, 0.97mL)and 
dimethylzinc ( 1.94mmol, 1.62mL) in 1M CH2Cl2. Following the general workup and 
deprotection, the crude mixture was purified by flash chromatography (SiO2, 10 g, 3% 
MeOH in CH2Cl2) methylated  alkyne was obtained as a white solid (0.14 g, 60%): TLC 
Rf = 0.2 3% MeOH in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 9.13 (s, 1H), 8.91 (s, 2H), 
7.79 (d, J = 2.3 Hz, 1H), 7.42 (dd, J = 8.4, 2.3, 1H), 6.96 (d, J = 8.4 Hz, 1H), 4.20 (qd, J 
= 7.0, 2.3 Hz, 1H), 3.88 (s, 3H), 2.24 (d, J = 2.5 Hz, 1H), 1.46 (d, J = 7.0 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ 157.0, 157.0, 154.6, 134.2, 132.4, 126.7, 126.6, 126.5, 111.4, 
87.0, 70.4, 55.8, 25.7, 22.8; IR (neat cm-1) 3265, 3046, 2832, 1889, 1605, 1252, 724. 
HRMS (DART, M+ + H) m/z 239.1207 (calculated for C15H114N2O, 239.1184). 
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According to the general methylation protocol, alkynol (0.5mmol, 0.16g) in 0.1M CH2Cl2 
was added to the pre-mixed solution of TiCl4 ( 0.5mmol, 0.5mL) and dimethylzinc 
(1.0mmol, 0.9mL) in 0.1M CH2Cl2. Following the general workup and deprotection, the 
crude mixture was purified by flash chromatography (SiO2, 10 g, 3% MeOH in CH2Cl2) 
methylated alkyne was obtained as a pale yellow solid (0.12 g, 60%): TLC Rf = 0.5 (3% 
MeOH in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.96 (s, 1H), 8.53 (s, 1H), 8.38 (s, 1H), 
8.22 (d, J = 2.3 Hz, 1H), 7.86 (dd, J = 8.5, 2.3 Hz, 1H), 6.90 (d, J = 8.6 Hz, 1H), 4.18 
(qd, J = 7.0, 2.5 Hz, 1H), 3.83 (s, 3H), 2.25 (d, J = 2.5 Hz, 1H), 1.45 (d, J = 7.0 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 157.7, 152.7, 144.1, 142.1, 141.8, 131.8, 128.9, 126.8, 
126.5, 110.9, 87.1, 70.1, 55.7, 25.6, 22.6; IR(neat cm-1) 3182, 3055, 2973, 2875, 2101, 
1605, 1248, 1126, 1013, 812, 713; HRMS (DART, M+ + H) m/z 239.1212 (calculated for 
C17H17NO2, 239.1184). 
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According to the general methylation protocol, alkynol (0.6mmol, 0.2g) in 0.1M CH2Cl2 
was added to the pre-mixed solution of TiCl4 (0.6mmol, 0.6mL) and dimethylzinc 
(1.2mmol, 1mL) in 0.1M CH2Cl2. Following the general workup and deprotection, the 
crude mixture was purified by flash chromatography (SiO2, 15 g, 3% MeOH in CH2Cl2) 
methylated alkyne was obtained as a yellow oil (0.16 g, 65%): TLC Rf = 0.2 (3% MeOH 
in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.61 (s, 2H), 7.45 (d, J = 4.1 Hz, 2H), 7.00 (s, 
1H), 6.92 (s, 1H), 3.90 (s, 3H), 3.74 (q, J = 6.7 Hz, 1H), 3.57 (s, 3H), 2.27 (s, 1H), 1.50 
(d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 153.3, 149.8, 146.2, 145.6, 139.1, 
133.0, 124.2, 120.2, 111.7, 86.9, 70.8, 61.0, 56.2, 31.7, 24.4; IR(neat cm-1) 3299, 3050, 
2975, 2933, 2873, 2837, 2003.75, 1586, 1406, 1264, 1139, 734; HRMS (DART, M+ + H) 
m/z 268.1336 (calculated for C17H17NO2, 268.1338). 
 
 
 
According to the general methylation protocol, alkynol (6.3mmol, 2.0g) in 0.1M CH2Cl2 
was added to the pre-mixed solution of TiCl4 (6.3mmol, 6.3mL)and dimethylzinc (12.6 
mmol, 10.5mL) in 1M CH2Cl2. Following the general workup and deprotection, the crude 
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mixture was purified by flash chromatography (SiO2, 20 g, 3% MeOH in CH2Cl2) 
methylated  alkyne was obtained as a yellow oil (1.0 g, 62%): TLC Rf = 0.2 (3% MeOH 
in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.63 (d, J = 5.4 Hz, 2H), 7.62 (d, J = 6.1 Hz, 
2H), 7.11 (d, J = 1.4 Hz, 1H), 6.93 (d, J = 1.6 Hz, 1H), 6.03 (d, J = 1.5 Hz, 2H), 3.73 (qd, 
J = 7.1, 2.4 Hz, 1H), 2.28 (d, J = 2.5 Hz, 1H), 1.50 (d, J = 7.1 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 150.3, 148.8, 144.5, 143.5, 137.6, 122.3, 119.5, 118.8, 108.2, 101.6, 
86.9, 70.8, 31.7, 24.6; IR(neat cm-1) 3200, 3026, 2929, 2786, 2106, 1737, 1596, 1402, 
1197, 1040, 938, 823, 623; HRMS (DART, M+ + H) m/z 257.1055 (calculated for 
C16H13NO2, 257.1025). 
 
 
According to the general methylation protocol, alkynol (1.0mmol, 0.32g) in 0.1M CH2Cl2 
was added to the pre-mixed solution of TiCl4 (1.0mmol, 1mL) and dimethylzinc 
(2.0mmol, 1.6mL) in 1M CH2Cl2. Following the general workup and deprotection, the 
crude mixture was purified by flash chromatography (SiO2, 15 g, 3% MeOH in CH2Cl2) 
methylated alkyne was obtained as a pale white solid (0.14 g, 56%): TLC Rf = 0.3 (3% 
MeOH in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 9.10 (s, 1H), 9.02 (s, 2H), 7.02 (s, 1H), 
6.90 (s, 1H), 6.00 (s, 2H), 3.70 (qd, J = 7.1, 2.4 Hz, 1H), 2.27 (d, J = 2.5 Hz, 1H), 1.46 
(d, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 157.4, 155.4, 148.7, 144.2, 137.9, 
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129.8, 118.2, 115.4, 108.2, 101.7, 86.6, 70.9, 31.5, 24.4; IR(neat cm-1) 3200, 2910, 2877, 
2787, 1726, 1494, 1407, 1349, 1262, 1176, 1045, 940, 855, 718; HRMS (DART, M+ + H) 
m/z 253.0968 (calculated for C15H12N2O2, 253.0977). 
 
 
 
According to the general methylation protocol, alkynol (1.11mmol, 0.35g) in 0.1M 
CH2Cl2 was added to the pre-mixed solution of TiCl4 (1.11mmol, 1.1mL) and 
dimethylzinc (2.22mmol, 1.9mL) in 1M CH2Cl2. Following the general workup and 
deprotection, the crude mixture was purified by flash chromatography (SiO2, 15 g, 3% 
MeOH in CH2Cl2) methylated alkyne was obtained as a yellow oil (0.17 g, 62%): TLC Rf 
= 0.1 (3% MeOH in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.57 (s, 1H), 7.45 (s, 1H), 
7.20 (d, J = 8.2 Hz, 1H), 7.02 (s, 1H), 6.87 (d, J = 8.4 Hz, 1H), 4.16 (q, J = 6.4 Hz, 1H), 
3.83 (s, 3H), 3.60 (s, 3H), 2.18 (s, 1H), 1.42 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 156.0, 138.8, 133.5, 131.5, 128.3, 128.2, 127.6, 122.3, 110.7, 87.3, 70.0, 55.7, 
32.5, 25.6, 22.8;  IR(neat cm-1) 3283, 2973, 2931, 2837, 1612, 1490, 1249, 1024, 813, 
650; HRMS (DART, M+ + H) m/z 241.1362 (calculated for C15H16N2O, 241.1341). 
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According to the general methylation protocol, alkynol (1.0mmol, 0.32g) in 0.1M CH2Cl2 
was added to the pre-mixed solution of TiCl4 (1.0mmol, 1.0mL) and dimethylzinc 
(2.0mmol, 1.6mL) in 1M CH2Cl2. Following the general workup and deprotection, the 
crude mixture was purified by flash chromatography (SiO2, 20 g, 3% MeOH in CH2Cl2) 
methylated alkyne  was obtained as a colorless oil (0.17 g, 65%): TLC Rf = 0.8 (3% 
MeOH in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.47 (s, 1H), 7.09 (d, J = 8.3 Hz, 1H), 
6.89 (d, J = 8.3 Hz, 1H), 4.19 (q, J = 6.8 Hz, 1H), 3.85 (s, 3H), 2.38 (s, 3H), 2.25 (s, 1H), 
2.20 (s, 0H), 1.44 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 165.0, 159.0, 
155.5, 131.6, 128.8, 128.6, 122.9, 116.5, 110.8, 87.4, 69.9, 55.7, 25.6, 22.9, 11.7, 11.0;  
IR(neat cm-1) 3292, 2973, 2931, 2837, 2125, 1606, 1505, 1246, 1130, 1026, 637; HRMS 
(DART, M+ + H) m/z 256.1361 (calculated for C16H17NO2, 256.1338). 
 
 
Deoxygenation 
 To a 100mL flame dried flask was added the TMS- protected alkynol dissolved in 
anhydrous 0.1M CH2Cl2 and cooled to 0 oC. BF3.OEt2 was slowly added followed by 
Et3SiH. Equivalence of lewis acid and triethylsilane ratio varies relative to the number of 
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heteroatoms present. After addition, the reaction mixture was brought to room 
temperature followed by heating to 41 oC for ~2hr. The reaction was quenched with 
sat.NaHCO3, extracted with EtOAc and dried with the MgSO4. After rotoevaporation, the 
crude products were subjected to deprotection as described in the methylation protocol. 
 
According to general deoxygenation protocol, alkynol (1.0mmol, 0.31g) dissolved in 
0.1M CH2Cl2 was subjected to deoxygenation with BF3.OEt2 (4.0mmol, 1.3mL) and 
triethylsilane (2.0mmol, 0.32mL) at 41 oC. Following the general workup and 
deprotection, the crude mixture was purified by flash chromatography   (SiO2, 15 g, 50% 
EtOAc in Hexane) deoxygenated alkyne was obtained as a white solid (0.17 g, 74%): 
TLC Rf = 0.3 (50% EtOAc in Hexane); 1H NMR (500 MHz, CDCl3) δ 8.59 (d, J = 4.2 
Hz, 2H), 7.80 (s, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.45 (d, J = 4.9 Hz, 2H), 6.90 (d, J = 8.4 
Hz, 1H), 3.85 (s, 3H), 3.60 (s, 2H), 2.21 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 157.8, 
150.3, 148.0, 130.4, 127.6, 126.7, 125.5, 121.2, 110.6, 81.6, 71.2, 55.7, 19.5;  IR(neat cm-
1) 3164, 2999, 2917, 2834, 2110, 1594, 1508, 1306, 804, 665; HRMS (DART, M+ + H) 
m/z 224.1071 (calculated for C15H13NO, 224.1075). 
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According to general deoxygenation protocol, alkynol (0.9mmol, 0.27g) dissolved in 
0.1M CH2Cl2 was subjected to deoxygenation with BF3.OEt2 (4.3mmol, 1.3mL) and 
triethylsilane (2.1mmol, 0.34mL) at 41 oC. Following the general workup and 
deprotection, the crude mixture was purified by flash chromatography   (SiO2, 10 g, 50% 
EtOAc in Hexane) deoxygenated alkyne was obtained as a pale yellow solid (0.15 g, 
76%): TLC Rf = 0.5 (50% EtOAc in Hexane); 1H NMR (500 MHz, CDCl3) δ 8.99 (s, 1H), 
8.56 (s, 1H), 8.42 (s, 1H), 8.17 (s, 1H), 7.91 (d, J = 10.4 Hz, 1H), 6.95 (d, J = 8.5 Hz, 
1H), 3.89 (s, 3H), 3.62 (d, J = 2.5 Hz, 2H), 2.21 (t, J = 2.5 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 158.3, 152.4, 143.9, 142.1, 141.6, 128.7, 127.4, 126.8, 125.2, 110.3, 81.5, 71.1, 
55.5, 19.4;  IR(neat cm-1) 3201, 3071, 2975, 2933, 2842, 2205, 1607, 1276, 1116, 1018, 
809, 697, 433; HRMS (DART, M+ + H) m/z 225.1050 (calculated for C14H12N2O, 
225.1028). 
 
According to general deoxygenation protocol, alkynol (0.34mmol, 0.11g) dissolved in 
0.1M CH2Cl2 was subjected to deoxygenation with BF3.OEt2 (1.4mmol, 0.17mL) and 
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triethylsilane (0.7mmol, 0.11mL) at 41 oC. Following the general workup and 
deprotection, the crude mixture was purified by flash chromatography   (SiO2, 7 g, 50% 
EtOAc in Hexane) deoxygenated alkyne was obtained as a brownish oil (0.05 g, 67%): 
TLC Rf = 0.3 (50% EtOAc in Hexane); 1H NMR (500 MHz, CDCl3) δ 8.62 (d, J = 5.6 Hz, 
2H), 7.45 (d, J = 6.0 Hz, 2H), 7.18 (s, 1H), 7.00 (s, 1H), 6.96 (s, 1H), 3.84 (s, 3H), 3.63 
(d, J = 2.4 Hz, 2H), 2.21 (t, J = 2.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 160.6, 150.4, 
148.2, 140.0, 138.7, 121.9, 119.2, 114.2, 111.4, 81.5, 71.2, 55.6, 25.1;  IR(neat cm-1) 
3288, 2959, 2931, 2837, 2113, 1592, 1406, 1217, 1049, 816, 627; HRMS (DART, M+ + 
H) m/z 224.1100 (calculated for C15H13NO, 224.1075). 
 
 
 
According to general deoxygenation protocol, alkynol (1.0mmol, 0.35g) dissolved in 
0.1M CH2Cl2 was subjected to deoxygenation with BF3.OEt2 (5.0mmol, 1.7mL) and 
triethylsilane (2.5mmol, 0.41mL) at 41 oC. Following the general workup and 
deprotection, the crude mixture was purified by flash chromatography   (SiO2, 10 g, 50% 
EtOAc in Hexane) deoxygenated alkyne was obtained as a yellow brownish solid (0.2 g, 
76%): TLC Rf = 0.3 (50% EtOAc in Hexane); 1H NMR (500 MHz, CDCl3) δ 8.62 (d, J = 
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6.1 Hz, 2H), 7.46 (d, J = 6.1 Hz, 2H), 6.97 (d, J = 1.9 Hz, 1H), 6.91 (d, J = 2.0 Hz, 1H), 
3.91 (s, 3H), 3.60 (d, J = 2.7 Hz, 2H), 3.58 (s, 3H), 2.21 (t, J = 2.7 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ 153.4, 149.6, 146.3, 145.7, 133.0, 132.6, 124.3, 121.3, 112.7, 81.8, 
71.1, 61.1, 56.2, 24.9; IR(neat cm-1) 3285, 3034, 2908, 2885, 2836, 2117, 1711, 1404, 
1264, 1132, 994, 816, 627; HRMS (DART, M+ + H) m/z 254.1196 (calculated for 
C16H15NO2, 254.1181). 
 
 
According to general deoxygenation protocol, alkynol (0.75mmol, 0.24g) dissolved in 
0.1M CH2Cl2 was subjected to deoxygenation with BF3.OEt2 (3.7mmol, 1.2mL) and 
triethylsilane (1.9mmol, 0.30mL) at 41 oC. Following the general workup and 
deprotection, the crude mixture was purified by flash chromatography   (SiO2, 7 g, 50% 
EtOAc in Hexane) deoxygenated alkyne was obtained as a pale white solid (0.13 g, 
74%): TLC Rf = 0.3 (50% EtOAc in Hexane); 1H NMR (500 MHz, CDCl3) δ 8.62 (d, J = 
5.4 Hz, 2H), 7.60 (d, J = 5.9 Hz, 2H), 7.06 (s, 1H), 6.87 (s, 1H), 6.01 (s, 2H), 3.55 (d, J = 
2.3 Hz, 2H), 2.20 (t, J = 2.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 150.3, 148.8, 144.5, 
143.3, 130.8, 122.2, 119.7, 119.5, 109.2, 101.6, 81.8, 71.1, 24.8;  IR(neat cm-1) 3229, 
3069, 3031, 2989, 2917, 2114, 1703, 1599, 1407, 1256, 1094, 944, 815, 652; HRMS 
(DART, M+ + H) m/z 238.0883 (calculated for C15H11NO2, 238.0868). 
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According to general deoxygenation protocol, alkynol (0.51mmol, 0.16g) dissolved in 
0.1M CH2Cl2 was subjected to deoxygenation with BF3.OEt2 (2.0mmol, 0.26mL) and 
triethylsilane (1.0mmol, 0.16mL) at 41 oC. Following the general workup and 
deprotection, the crude mixture was purified by flash chromatography   (SiO2, 7 g, 3% 
MeOH in CH2Cl2) deoxygenated alkyne was obtained as a yellow oil (0.08 g, 70%): TLC 
Rf = 0.1 (50% EtOAc in Hexane); 1H NMR (500 MHz, CDCl3) δ 7.53 (d, J = 2.1 Hz, 1H), 
7.48 (s, 1H), 7.24 – 7.21 (m, 1H), 7.02 (s, 1H), 6.88 (d, J = 8.4 Hz, 1H), 3.85 (s, 3H), 
3.61 (s, 3H), 3.58 (d, J = 2.6 Hz, 2H), 2.17 (t, J = 2.7 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 156.8, 138.8, 133.5, 129.4, 128.5, 127.6, 125.1, 122.2, 110.3, 81.6, 71.1, 55.7, 
32.6, 19.4;  IR(neat cm-1) 3215, 2969, 2930, 2884, 1658, 1466, 1127, 950, 816, 627; 
HRMS (DART, M+ + H) m/z 227.1184 (calculated for C14H14N2O, 227.1204). 
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According to general deoxygenation protocol, alkynol (0.33mmol, 0.11g) dissolved in 
0.1M CH2Cl2 was subjected to deoxygenation with BF3.OEt2 (1.7mmol, 0.21mL) and 
triethylsilane (0.8mmol, 0.13mL) at 41 oC. Following the general workup and 
deprotection, the crude mixture was purified by flash chromatography   (SiO2, 7g, 50% 
EtOAc in Hexane) deoxygenated alkyne was obtained as a white solid (0.06 g, 74%): 
TLC Rf = 0.7 (50% EtOAc in Hexane); 1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 2.1 
Hz, 1H), 7.10 (dd, J = 8.3, 2.2 Hz, 1H), 6.89 (d, J = 8.3 Hz, 1H), 3.85 (s, 3H), 3.59 (d, J = 
2.4 Hz, 2H), 2.38 (s, 3H), 2.25 (s, 3H), 2.18 (t, J = 2.7 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 165.0, 159.0, 156.3, 129.8, 128.7, 125.2, 122.7, 116.5, 110.4, 81.7, 71.0, 55.7, 
19.4, 11.7, 11.0;  IR(neat cm-1) 3243, 3020, 2927, 2838, 2115, 1632, 1504, 1246, 1114, 
1027, 815, 684; HRMS (DART, M+ + H) m/z 242.1195 (calculated for C15H15NO2, 
242.1181). 
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According to general deoxygenation protocol, alkynol (0.44mmol, 0.13g) dissolved in 
0.1M CH2Cl2 was subjected to deoxygenation with BF3.OEt2 (1.8mmol, 0.22mL) and 
triethylsilane (0.9mmol, 0.14mL) at 41 oC. Following the general workup and 
deprotection, the crude mixture was purified by HPLC chromatogaraphy with 60% ACN 
in water; deoxygenated alkyne was obtained as a pale white solid (0.06 g, 66%): TLC Rf 
= 0.4 (50% EtOAc in Hexane); 1H NMR (500 MHz, CDCl3) δ 8.55 (d, J = 4.5 Hz, 1H), 
7.40 (d, J = 5.0 Hz, 1H), 7.33 (d, J = 3.6 Hz, 0H), 6.98 (d, J = 3.2 Hz, 1H), 3.78 (d, J = 
2.3 Hz, 2H), 2.24 (t, J = 2.4 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 150.6, 141.5, 141.2, 
140.1, 126.8, 125.4, 119.7, 80.5, 71.1, 20.3;  IR(neat cm-1) 3181, 3072, 3040, 3017, 2112, 
1592, 1414, 1219, 991, 800, 689, 463; HRMS (DART, M+ + H) m/z 200.0556 (calculated 
for C12H9NS, 200.0534). 
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